{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T06:46:46Z","timestamp":1791269206916,"version":"4.1.0"},"update-to":[{"DOI":"10.1002\/14651858.cd003897.pub2","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2010,1,20]],"date-time":"2010-01-20T00:00:00Z","timestamp":1263945600000}}],"reference-count":409,"publisher":"Wiley","issue":"5","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd003897.pub3","type":"journal-article","created":{"date-parts":[[2010,1,18]],"date-time":"2010-01-18T11:21:47Z","timestamp":1263813707000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":70,"title":["Interleukin 2 receptor antagonists for kidney transplant recipients"],"prefix":"10.1002","volume":"2014","author":[{"given":"Angela C","family":"Webster","sequence":"first","affiliation":[{"name":"The University of Sydney at Westmead; Centre for Transplant and Renal Research, Westmead Millennium Institute; Westmead NSW Australia 2145"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenn P","family":"Ruster","sequence":"additional","affiliation":[{"name":"The Children's Hospital at Westmead; Centre for Kidney Research; Locked Bag 4001 Westmead NSW Australia 2145"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard G","family":"McGee","sequence":"additional","affiliation":[{"name":"The University of Sydney; Sydney School of Public Health; Sydney NSW Australia 2006"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra L","family":"Matheson","sequence":"additional","affiliation":[{"name":"The Children's Hospital at Westmead; Centre for Kidney Research; Locked Bag 4001 Westmead NSW Australia 2145"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gail Y","family":"Higgins","sequence":"additional","affiliation":[{"name":"The Children's Hospital at Westmead; Cochrane Renal Group, Centre for Kidney Research; Locked Bag 4001 Westmead NSW Australia 2045"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narelle S","family":"Willis","sequence":"additional","affiliation":[{"name":"The Children's Hospital at Westmead; Cochrane Renal Group, Centre for Kidney Research; Locked Bag 4001 Westmead NSW Australia 2045"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy R","family":"Chapman","sequence":"additional","affiliation":[{"name":"Westmead Millennium Institute, The University of Sydney at Westmead; Centre for Transplant and Renal Research; Darcy Rd Westmead NSW Australia 2145"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan C","family":"Craig","sequence":"additional","affiliation":[{"name":"The University of Sydney; Sydney School of Public Health; Sydney NSW Australia 2006"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,1,20]]},"reference":[{"issue":"6","key":"10.1002\/14651858.CD003897.pub3-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1093\/ndt\/gfm873","article-title":"CMV infections after two doses of daclizumab versus thymoglobulin in renal transplant patients receiving mycophenolate mofetil, steroids and delayed cyclosporine A","volume":"23","author":"Abou-Ayache","year":"2008","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Suppl 11","key":"10.1002\/14651858.CD003897.pub3-BIB0002|cit2","first-page":"187","article-title":"Two-dose daclizumab induction treatment versus thymoglobuline in renal transplant patients receiving a mycophenolate mofetil based immunosuppression [abstract no: 121]","volume":"5","author":"Abou-Ayache","year":"2005","journal-title":"American Journal of Transplantation"},{"issue":"6","key":"10.1002\/14651858.CD003897.pub3-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1034\/j.1600-6143.2002.20612.x","article-title":"Limited dose monoclonal IL-2R antibody induction protocol after primary kidney transplantation","volume":"2","author":"Ahsan","year":"2002","journal-title":"American Journal of Transplantation"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD003897.pub3-BIB0004|cit4","first-page":"469","article-title":"Limited dose monoclonal IL-2R antibody induction in kidney transplantation - a prospective, randomized, controlled clinical trial [abstract]","volume":"2","author":"Ahsan","year":"2002","journal-title":"American Journal of Transplantation"},{"issue":"1","key":"10.1002\/14651858.CD003897.pub3-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1097\/01.tp.0000225803.04995.2b","article-title":"Calcineurin inhibitor avoidance with daclizumab, mycophenolate mofetil, and prednisolone in DR-matched de novo kidney transplant recipients","volume":"82","author":"Asberg","year":"2006","journal-title":"Transplantation"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD003897.pub3-BIB0006|cit6","first-page":"iv264","article-title":"Calcineurin inhibitor-avoidance with daclizumab, mycophenolate mofetil and prednisolone in DR matched de novo kidney transplant recipients [abstract no: SP737]","volume":"21","author":"Asberg","year":"2006","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD003897.pub3-BIB0007|cit7","first-page":"788","article-title":"Large, prospective study evaluating steroid-free immunosuppression with tacrolimus\/basiliximab and tacrolimus\/mmf compared with tacrolimus\/mmf\/steroids in renal transplantation [abstract]","volume":"18","author":"Klinger","year":"2003","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Nov","key":"10.1002\/14651858.CD003897.pub3-BIB0008|cit8","first-page":"9A","article-title":"Two steroid-free immunosuppressive regimens (basiliximab\/tacrolimus and tacrolimus\/mmf) in comparison to tacrolimus\/MMF\/steroid therapy after renal transplantation [abstract]","volume":"14","author":"Kramer","year":"2003","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Oct","key":"10.1002\/14651858.CD003897.pub3-BIB0009|cit9","first-page":"289A","article-title":"1-year-follow-up of two steroid-free immunosuppressive regimens - basiliximab\/tacrolimus and tacrolimus\/MMR - in comparison to tacrolimus\/MMF\/steroids after renal transplantation [abstract no: F-PO1026]","volume":"15","author":"Kramer","year":"2004","journal-title":"Journal of the American Society of Nephrology"},{"issue":"4","key":"10.1002\/14651858.CD003897.pub3-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1016\/j.transproceed.2005.03.139","article-title":"Steroid withdrawal or steroid avoidance in renal transplant recipients: Focus on tacrolimus-based immunosuppressive regimens","volume":"37","author":"Kramer","year":"2005","journal-title":"Transplantation Proceedings"},{"issue":"12","key":"10.1002\/14651858.CD003897.pub3-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1097\/01.tp.0000188300.26762.74","article-title":"Two corticosteroids-free regimens - tacrolimus monotherapy after basiliximab administration and tacrolimus\/mycophenolate mofetil - in comparison with a standard triple regimen in renal transplantation: results of the Atlas Study","volume":"80","author":"Vitko","year":"2005","journal-title":"Transplantation"},{"issue":"Suppl 5","key":"10.1002\/14651858.CD003897.pub3-BIB0012|cit12","first-page":"312","article-title":"Comparison of two steroid-free regimens - basiliximab\/tacrolimus and tacrolimus\/mmf - with tacrolimus\/mmf\/steroid therapy after renal transplantation [abstract]","volume":"3","author":"Vitko","year":"2003","journal-title":"American Journal of Transplantation"},{"issue":"88","key":"10.1002\/14651858.CD003897.pub3-BIB0013|cit13","first-page":"356","article-title":"[Cytokines and growth factors serum level and renal allograft function (preliminary report)] [Polish]","volume":"15","author":"Baczkowska","year":"2003","journal-title":"Polski Merkuriusz Lekarski"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD003897.pub3-BIB0014|cit14","first-page":"309","article-title":"Daclizumab allows for a protocol with low-dose cyclosporine in low rejection-risk kidney recipients - preliminary data [abstract]","volume":"17","author":"Baczkowska","year":"2002","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"6","key":"10.1002\/14651858.CD003897.pub3-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1016\/S0041-1345(03)00807-8","article-title":"The role of the protocol biopsies in renal allograft recipients","volume":"35","author":"Baczkowska","year":"2003","journal-title":"Transplantation Proceedings"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD003897.pub3-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1097\/01.tp.0000331097.51512.7c","article-title":"Untreated subclinical, borderline rejection in 12 and 36-month protocol biopsies is not associated with progressive loss of GFR at 5-year's follow-up [abstract no: 1755]","volume":"86","author":"Baczkowska","year":"2008","journal-title":"Transplantation"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD003897.pub3-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1097\/00007890-200407271-00849","article-title":"Serum TGF-b1 correlates with chronic histopathological lesions in protocol biopsies in kidney allograft recipients [abstract]","volume":"78","author":"Baczkowska","year":"2004","journal-title":"Transplantation."},{"issue":"Suppl 4","key":"10.1002\/14651858.CD003897.pub3-BIB0018|cit18","first-page":"iv263","article-title":"The role of the protocol biopsies in renal allograft recipients: three-years\u2019 follow-up [abstract no: SP736]","volume":"21","author":"Baczkowska","year":"2006","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"2","key":"10.1002\/14651858.CD003897.pub3-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.transproceed.2005.01.030","article-title":"Serum TGF-beta1 correlates with chronic histopathological lesions in protocol biopsies of kidney allograft recipients","volume":"37","author":"Baczkowska","year":"2005","journal-title":"Transplantation Proceedings"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD003897.pub3-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1097\/00007890-200407271-01255","article-title":"Induction immunosuppression with interleukin-2 receptor antibodies (basiliximab) in renal transplant recipients [abstract]","volume":"78","author":"Bernarde","year":"2004","journal-title":"Transplantation"},{"issue":"1","key":"10.1002\/14651858.CD003897.pub3-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/S0041-1345(02)04041-1","article-title":"The effect of anti-CD25 monoclonal antibody (Simulect) to the lymphocytes in the peripheral blood of the recipients of kidney transplantation","volume":"35","author":"Bingyi","year":"2003","journal-title":"Transplantation Proceedings"},{"issue":"1","key":"10.1002\/14651858.CD003897.pub3-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/S0041-1345(02)03769-7","article-title":"Randomised trial of Simulect versus placebo for control of acute rejection in renal allograft recipients","volume":"35","author":"Bingyi","year":"2003","journal-title":"Transplantation Proceedings"},{"issue":"19","key":"10.1002\/14651858.CD003897.pub3-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1056\/NEJMoa060068","article-title":"Rabbit antithymocyte globulin versus basiliximab in renal transplantation","volume":"355","author":"Brennan","year":"2006","journal-title":"New England Journal of Medicine"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD003897.pub3-BIB0024|cit24","first-page":"279","article-title":"5 Year outcomes in a randomized trial comparing rabbit antithymocyte globulin and basiliximab in kidney transplant recipients: Linking clinical trial data with registry data: 798. [Abstract]","volume":"86","author":"Brennan","year":"2008","journal-title":"Transplantation"},{"issue":"16","key":"10.1002\/14651858.CD003897.pub3-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1056\/NEJMc0805714","article-title":"Long-Term results of rabbit antithymocyte globulin and basiliximab induction","volume":"359","author":"Brennan","year":"2008","journal-title":"New England Journal of Medicine"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD003897.pub3-BIB0026|cit26","first-page":"238","article-title":"A prospective randomized multicenter comparison of thymoglobulin versus Simulect for induction therapy in high risk renal transplant recipients [abstract no:398]","volume":"2","author":"Brennan","year":"2002","journal-title":"American Journal of Transplantation"},{"issue":"Suppl 5","key":"10.1002\/14651858.CD003897.pub3-BIB0027|cit27","first-page":"438","article-title":"Thymoglobulin versus Simulect for induction immunosuppression in cadaveric renal transplant recipients: expanded results from a prospective, randomized, multicenter trial [abstract]","volume":"3","author":"Brennan","year":"2003","journal-title":"American Journal of Transplantation"},{"key":"10.1002\/14651858.CD003897.pub3-BIB0028|cit28","unstructured":"Brennan DC Thymoglubulin Induction Study Group A prospective, randomized, multicenter study of thymoglobulin compared to Simulect for induction immunosuppression: preliminary results [abstract] XIXth International Congress of the Transplantation Society; 2002 Aug 25-30; Miami, FL 2002"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD003897.pub3-BIB0029|cit29","first-page":"234","article-title":"Novel approach to obtain long-term outcomes of patients in a randomized trial comparing thymoglobulin and basiliximab in kidney transplant using registry data [abstract no: 334]","volume":"7","author":"Brennan","year":"2007","journal-title":"American Journal of Transplantation"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD003897.pub3-BIB0030|cit30","first-page":"321","article-title":"Thymoglobulin has its greatest efficacy in recipients of standard criteria donors and donors without hypertension [abstract no: 536]","volume":"8","author":"Hardinger","year":"2008","journal-title":"American Journal of Transplantation"},{"issue":"19","key":"10.1002\/14651858.CD003897.pub3-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1056\/NEJMe068188","article-title":"Rabbit antithymocyte globulin or basiliximab for induction therapy?","volume":"355","author":"Josephson","year":"2006","journal-title":"New England Journal of Medicine"},{"issue":"6","key":"10.1002\/14651858.CD003897.pub3-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1056\/NEJMc063467","article-title":"Antithymocyte globulin versus basiliximab in renal transplantation","volume":"356","author":"Killen","year":"2007","journal-title":"New England Journal of Medicine"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD003897.pub3-BIB0033|cit33","first-page":"232","article-title":"Cost-effectiveness of thymoglobulin compared to basiliximab in kidney transplant using multicenter randomized trial data [abstract no: 326]","volume":"7","author":"Schnitzler","year":"2007","journal-title":"American Journal of Transplantation"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD003897.pub3-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1097\/00007890-200407271-01230","article-title":"Low-dose cyclosporine in conjunction with daclizumab, mycophenolate mofetil and corticosteroids is safe and effective in contrast to early cyclosporine withdrawal [abstract]","volume":"78","author":"Ekberg","year":"2004","journal-title":"Transplantation"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD003897.pub3-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1097\/00007890-200407271-01230","article-title":"The use of daclizumab and mycophenolate mofetil in combination with corticosteroids and cyclosporine (low dose versus low dose followed by withdrawal) to optimize renal function in recipients of renal allografts [abstract]","volume":"78","author":"Ekberg","year":"2004","journal-title":"Transplantation"},{"issue":"3","key":"10.1002\/14651858.CD003897.pub3-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1111\/j.1600-6143.2006.01645.x","article-title":"Cyclosporine sparing with mycophenolate mofetil, daclizumab and corticosteroids in renal allograft recipients: the CAESAR Study","volume":"7","author":"Ekberg","year":"2007","journal-title":"American Journal of Transplantation"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD003897.pub3-BIB0037|cit37","first-page":"410","article-title":"Association of three polymorphisms with acute kidney transplantation: an exploratory pharmacogenetic analysis of a randomized mulitcenter clinical trial (The CAESaR study)","volume":"6","author":"Grinyo","year":"2006","journal-title":"American Journal of Transplantation"},{"issue":"Suppl 11","key":"10.1002\/14651858.CD003897.pub3-BIB0038|cit38","first-page":"539","article-title":"The use of mycophenolate mofetil, daclizumab and corticosteroids with cyclosporine (low dose, low dose\/withdrawal and standard dose) to optimize renal function in renal allograft recipients - 18 month results [abstract no: 1507]","volume":"5","author":"Vincenti","year":"2005","journal-title":"American Journal of Transplantation"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD003897.pub3-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1097\/00007890-200407271-00442","article-title":"Steroid-free immunosuppression with daclizumab, tacrolimus and mmf is efficacious and improves cholesterol, glucose and bone mineral density - the CARMEN study [abstract]","volume":"78","author":"Budde","year":"2004","journal-title":"Transplantation"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD003897.pub3-BIB0040|cit40","first-page":"788","article-title":"The combination of daclizumab, tacrolimus, and MMF is an effective and safe steroid-free immunosuppressive regimen after renal transplantation. Results of a large multicentre trial [abstract]","volume":"18","author":"Cantarovich","year":"2003","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"4","key":"10.1002\/14651858.CD003897.pub3-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1016\/j.transproceed.2005.03.139","article-title":"Steroid withdrawal or steroid avoidance in renal transplant recipients: Focus on tacrolimus-based immunosuppressive regimens","volume":"37","author":"Kramer","year":"2005","journal-title":"Transplantation Proceedings"},{"key":"10.1002\/14651858.CD003897.pub3-BIB0042|cit42","unstructured":"Mourad GL Rostaing D Cantarovich H Neumayer H Rigotti P the Tacrolimus Steroidfree Study Group Immunosuppression without steroids: daclizumab\/tacrolimus\/MMF vs. tacrolimus\/MMF\/steroids in renal transplantation [abstract no: 12] 11th Congress of the European Society for Transplantation (ESOT); 2003 Sept 20-24; Venice, Italy 2003"},{"key":"10.1002\/14651858.CD003897.pub3-BIB0043|cit43","unstructured":"Pascual J Rigotti P Vialtel P Sanchez-Rructuoso A Escuin F The Bone Density Study Group Immunosuppression without steroids: a daclizumab, tacrolimus and MMF regimen prevents loss of bone mass following renal transplantation [abstract no 369] 11th Congress of the European Society for Transplantation (ESOT); 2003 Sept 20-24; Venice, Italy 2003"},{"issue":"Suppl 5","key":"10.1002\/14651858.CD003897.pub3-BIB0044|cit44","first-page":"199","article-title":"Immunosuppression without maintenance steroids prevents decline of bone mineral density following renal transplantation [abstract]","volume":"3","author":"Rigotti","year":"2003","journal-title":"American Journal of Transplantation"},{"issue":"7","key":"10.1002\/14651858.CD003897.pub3-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1097\/01.TP.0000154915.20524.0A","article-title":"Corticosteroid-free immunosuppression with tacrolimus, mycophenolate mofetil, and daclizumab induction in renal transplantation","volume":"79","author":"Rostaing","year":"2005","journal-title":"Transplantation"},{"issue":"Suppl 5","key":"10.1002\/14651858.CD003897.pub3-BIB0046|cit46","first-page":"312","article-title":"Steroid-free immunosuppression with a combination of daclizumab, tacrolimus and MMF is efficacious and safe: results of a large multicenter trial in renal transplantation [abstract]","volume":"3","author":"Rostaing","year":"2003","journal-title":"American Journal of Transplantation"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD003897.pub3-BIB0047|cit47","first-page":"495","article-title":"A steroid-free immunosuppressive regimen of daclizumab, tacrolimus and MMF prevents loss of bone mass following renal transplantation [abstract]","volume":"18","author":"Zaoui","year":"2003","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Abstracts","key":"10.1002\/14651858.CD003897.pub3-BIB0048|cit48","first-page":"850A","article-title":"Daclizumab two doses 0 and 4 days is efficacious to prevent rejection after kidney transplantation [abstract no: PUB163]","volume":"17","author":"Cerrillos","year":"2006","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD003897.pub3-BIB0049|cit49","first-page":"494","article-title":"Double filtration plasmapheresis with\/without daclizumab induction in the sensitized candidates of cadaveric renal transplantation: a randomized prospective trial [abstract]","volume":"18","author":"Chen","year":"2003","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Nov","key":"10.1002\/14651858.CD003897.pub3-BIB0050|cit50","first-page":"440A","article-title":"The effect of daclizumab in highly sensitive kidney recipients [abstract no: SA-PO652]","volume":"14","author":"Chen","year":"2003","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Suppl 8","key":"10.1002\/14651858.CD003897.pub3-BIB0051|cit51","first-page":"405","article-title":"Cellular phenotypes affected by induction therapy with campath-1h vs thymoglobulin vs Zenapax in kidney allograft recipients [abstract]","volume":"4","author":"Carreno","year":"2004","journal-title":"American Journal of Transplantation"},{"issue":"4","key":"10.1002\/14651858.CD003897.pub3-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1097\/01.tp.0000165847.05787.08","article-title":"A randomized trial of three renal transplant induction antibodies: early comparison of tacrolimus, mycophenolate mofetil, and steroid dosing, and newer immune-monitoring","volume":"80","author":"Ciancio","year":"2005","journal-title":"Transplantation"},{"issue":"Suppl 8","key":"10.1002\/14651858.CD003897.pub3-BIB0053|cit53","first-page":"266","article-title":"Randomized trial of three different induction regimens to prevent acute renal allograft rejection: early results [abstract]","volume":"4","author":"Ciancio","year":"2004","journal-title":"American Journal of Transplantation"},{"issue":"2","key":"10.1002\/14651858.CD003897.pub3-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1111\/j.1399-0012.2007.00774.x","article-title":"A randomized trial of thymoglobulin vs. alemtuzumab (with lower dose maintenance immunosuppression) vs. daclizumab in renal transplantation at 24 months of follow-up","volume":"22","author":"Ciancio","year":"2008","journal-title":"Clinical Transplantation"},{"issue":"Suppl 11","key":"10.1002\/14651858.CD003897.pub3-BIB0055|cit55","first-page":"569","article-title":"A randomized trial of three different antibody induction regimens in renal transplantation","volume":"5","author":"Ciancio","year":"2005","journal-title":"American Journal of Transplantation"},{"issue":"25","key":"10.1002\/14651858.CD003897.pub3-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"2683","DOI":"10.1056\/NEJMc0808481","article-title":"B-cell-depleting induction therapy and acute cellular rejection","volume":"360","author":"Clatworthy","year":"2009","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD003897.pub3-BIB0057|cit57","unstructured":"See Dacilizumab Double and Triple studies"},{"issue":"5","key":"10.1002\/14651858.CD003897.pub3-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1097\/00007890-200109150-00017","article-title":"Results of 3-year phase III clinical trials with daclizumab prophylaxis for prevention of acute rejection after renal transplantation","volume":"72","author":"Bumgardner","year":"2001","journal-title":"Transplantation"},{"issue":"4","key":"10.1002\/14651858.CD003897.pub3-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1097\/00007890-200108270-00014","article-title":"Daclizumab (humanized anti-IL2R alpha mAb) prophylaxis for prevention of acute rejection in renal transplant recipients with delayed graft function","volume":"72","author":"Bumgardner","year":"2001","journal-title":"Transplantation"},{"issue":"4","key":"10.1002\/14651858.CD003897.pub3-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1016\/S0041-1345(98)00264-4","article-title":"Placebo-controlled study of a humanized anti-TAC monoclonal antibody in dual therapy for prevention of acute rejection after renal transplantation","volume":"30","author":"Charpentier","year":"1998","journal-title":"Transplantation Proceedings"},{"issue":"1-2","key":"10.1002\/14651858.CD003897.pub3-BIB0063|cit61","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S0041-1345(98)01529-2","article-title":"Zenapax (daclizumab) reduces the incidence of acute rejection episodes and improves patient survival following renal transplantation. No 14874 and No 14393 Zenapax Study Groups","volume":"31","author":"Ekberg","year":"1999","journal-title":"Transplantation Proceedings"},{"issue":"2","key":"10.1002\/14651858.CD003897.pub3-BIB0061|cit62","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/j.1432-2277.2000.tb01056.x","article-title":"Daclizumab prevents acute rejection and improves patient survival post transplantation: 1 year pooled analysis","volume":"13","author":"Ekberg","year":"2000","journal-title":"Transplant International"},{"key":"10.1002\/14651858.CD003897.pub3-BIB0062|cit63","unstructured":"Ekberg H Backman L Tufveson G Tyden G on behalf of the NO 14874 and NO 14393 Zenapax Study Groups Daclizumab (Zenapax) reduces the incidence of acute rejection episodes following renal transplantation [abstract] XVII World Congress of the Transplantation Society; 1998 Jul 12-17; Montreal, Canada 1998"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD003897.pub3-BIB0064|cit64","first-page":"S71","article-title":"A randomized clinical trial of Zenapax for preventing acute rejection in renal transplantation [abstract]","volume":"3","author":"Hardie","year":"1997","journal-title":"Nephrology"},{"issue":"2","key":"10.1002\/14651858.CD003897.pub3-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1097\/00007890-199907270-00028","article-title":"Cytomegalovirus infections after treatment with daclizumab, an anti IL-2 receptor antibody, for prevention of renal allograft rejection. Roche Study Group","volume":"68","author":"Hengster","year":"1999","journal-title":"Transplantation"},{"issue":"1","key":"10.1002\/14651858.CD003897.pub3-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1097\/00007890-199901150-00019","article-title":"Reduction of acute renal allograft rejection by daclizumab. Daclizumab Double Therapy Study Group","volume":"67","author":"Nashan","year":"1999","journal-title":"Transplantation"},{"issue":"12","key":"10.1002\/14651858.CD003897.pub3-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1097\/00007890-199805131-00059","article-title":"Incidence of CMV infections during daclizumab treatment in renal allograft patients [abstract]","volume":"65","author":"Nashan","year":"1998","journal-title":"Transplantation"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD003897.pub3-BIB0068|cit68","first-page":"750A","article-title":"Three year outcome of the phase III clinical trials with Daclizumab [abstract]","volume":"10","author":"Vincenti","year":"1999","journal-title":"Journal of the American Society of Nephrology"},{"issue":"8 Suppl","key":"10.1002\/14651858.CD003897.pub3-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"S261","DOI":"10.1097\/00007890-200004271-00577","article-title":"Three year outcome of the phase III clinical trials with daclizumab [abstract]","volume":"69","author":"Vincenti","year":"2000","journal-title":"Transplantation"},{"issue":"5","key":"10.1002\/14651858.CD003897.pub3-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1016\/S0041-1345(98)00571-5","article-title":"Daclizumab: Outcome of phase III trials and mechanism of action","volume":"30","author":"Vincenti","year":"1998","journal-title":"Transplantation Proceedings"},{"issue":"8","key":"10.1002\/14651858.CD003897.pub3-BIB0071|cit71","first-page":"S180","article-title":"Pooled analysis of phase III studies of Zenapax (Daclizumab), a humanized anti-IL-2R antibody [abstract]","volume":"65","author":"Zenapax Double and Triple Therapy Study Group","year":"2002","journal-title":"Transplantation"},{"issue":"5","key":"10.1002\/14651858.CD003897.pub3-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1097\/00007890-200109150-00017","article-title":"Results of 3-year phase III clinical trials with daclizumab prophylaxis for prevention of acute rejection after renal transplantation","volume":"72","author":"Bumgardner","year":"2001","journal-title":"Transplantation"},{"issue":"4","key":"10.1002\/14651858.CD003897.pub3-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1097\/00007890-200108270-00014","article-title":"Daclizumab (humanized anti-IL2Ralpha mAb) prophylaxis for prevention of acute rejection in renal transplant recipients with delayed graft function","volume":"72","author":"Bumgardner","year":"2001","journal-title":"Transplantation"},{"issue":"1-2","key":"10.1002\/14651858.CD003897.pub3-BIB0076|cit74","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S0041-1345(98)01529-2","article-title":"Zenapax (daclizumab) reduces the incidence of acute rejection episodes and improves patient survival following renal transplantation. No 14874 and No 14393 Zenapax Study Groups","volume":"31","author":"Ekberg","year":"1999","journal-title":"Transplantation Proceedings"},{"issue":"2","key":"10.1002\/14651858.CD003897.pub3-BIB0074|cit75","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/j.1432-2277.2000.tb01056.x","article-title":"Daclizumab prevents acute rejection and improves patient survival post transplantation: 1 year pooled analysis","volume":"13","author":"Ekberg","year":"2000","journal-title":"Transplant International"},{"key":"10.1002\/14651858.CD003897.pub3-BIB0075|cit76","unstructured":"Ekberg H Backman L Tufveson G Tyden G on behalf of the NO 14874 and NO 14393 Zenapax Study Groups Daclizumab (Zenapax) reduces the incidence of acute rejection episodes following renal transplantation [abstract] XVII World Congress of the Transplantation Society; 1998 Jul 12-17; Montreal, Canada 1998"},{"issue":"2","key":"10.1002\/14651858.CD003897.pub3-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1097\/00007890-199907270-00028","article-title":"Cytomegalovirus infections after treatment with daclizumab, an anti IL-2 receptor antibody, for prevention of renal allograft rejection. Roche Study Group","volume":"68","author":"Hengster","year":"1999","journal-title":"Transplantation"},{"key":"10.1002\/14651858.CD003897.pub3-BIB0078|cit78","unstructured":"Kirkman RL Vincenti F Pescovitz MD Bumgardner G Gaston RS Light S A Phase I\/II Randomized, double blind, placebo controlled study of Zenapax in combination with cellCept, neoral and steroids 16th Annual Meeting. American Society of Transplant Physicians (ASTP); 1997 May 10-14; Chicago, ILL 1997 260"},{"key":"10.1002\/14651858.CD003897.pub3-BIB0079|cit79","unstructured":"Vincenti F Bi-Continental Triple Therapy HAT Study Group A phase III multicenter study of humanized anti-tac (HAT) for the prevention of rejection in primary cadaveric renal allograft recipients 16th Annual Meeting. American Society of Transplant Physicians (ASTP); 1997 May 10-14; Chicago, ILL 1997 260"},{"issue":"3","key":"10.1002\/14651858.CD003897.pub3-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1056\/NEJM199801153380304","article-title":"Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group","volume":"338","author":"Vincenti","year":"1998","journal-title":"New England Journal of Medicine"},{"issue":"Program and Abs","key":"10.1002\/14651858.CD003897.pub3-BIB0081|cit81","first-page":"750A","article-title":"Three year outcome of the phase III clinical trials with Daclizumab [abstract]","volume":"10","author":"Vincenti","year":"1999","journal-title":"Journal of the American Society of Nephrology"},{"issue":"8 Suppl","key":"10.1002\/14651858.CD003897.pub3-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"S261","DOI":"10.1097\/00007890-200004271-00577","article-title":"Three year outcome of the phase III clinical trials with daclizumab [abstract]","volume":"69","author":"Vincenti","year":"2000","journal-title":"Transplantation"},{"issue":"5","key":"10.1002\/14651858.CD003897.pub3-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1016\/S0041-1345(98)00571-5","article-title":"Daclizumab: Outcome of phase III trials and mechanism of action","volume":"30","author":"Vincenti","year":"1998","journal-title":"Transplantation Proceedings"},{"issue":"8","key":"10.1002\/14651858.CD003897.pub3-BIB0084|cit84","first-page":"S180","article-title":"Pooled analysis of phase III studies of Zenapax (Daclizumab), a humanized anti-IL-2R antibody [abstract]","volume":"65","author":"Zenapax Double and Triple Therapy Study Group","year":"2002","journal-title":"Transplantation"},{"key":"10.1002\/14651858.CD003897.pub3-BIB0085|cit85","unstructured":"de Boccardo G Latin American study of the efficacy and safety of Simulect in kidney transplant recipients [abstract] XIXth International Congress of the Transplantation Society; 2002 Aug 25-30; Miami, FL 2002"},{"issue":"Suppl 11","key":"10.1002\/14651858.CD003897.pub3-BIB0086|cit86","first-page":"185","article-title":"Low dose cyclosporine regimen with daclizumab induction and mycophenolate mofetil after kidney transplantation - impact on renal function and rejection episodes [abstract no: 113]","volume":"5","author":"Fangmann","year":"2005","journal-title":"American Journal of Transplantation"},{"issue":"Suppl 8","key":"10.1002\/14651858.CD003897.pub3-BIB0087|cit87","first-page":"353","article-title":"Impact of daclizumab and low dose cyclosporine in combination with mycophenolate mofetil and steroids on renal function after kidney transplantation [abstract]","volume":"4","author":"Fangmann","year":"2004","journal-title":"American Journal of Transplantation"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD003897.pub3-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1097\/00007890-200407271-00744","article-title":"Impact of daclizumab and low dose cyclosporine in combination with mycophenolate mofetil and steroids on renal function after kidney transplantation [abstract]","volume":"78","author":"Fangmann","year":"2004","journal-title":"Transplantation"},{"issue":"8 Suppl","key":"10.1002\/14651858.CD003897.pub3-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"S157","DOI":"10.1097\/00007890-200004271-00169","article-title":"A randomized prospective trial of OKT3 vs basiliximab for induction therapy in renal transplantation [abstract]","volume":"69","author":"Flechner","year":"2000","journal-title":"Transplantation"},{"issue":"7-8","key":"10.1002\/14651858.CD003897.pub3-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"3209","DOI":"10.1016\/S0041-1345(01)02366-1","article-title":"Low rate of acute rejection and cytomegalovirus infection in kidney transplant recipients with basiliximab","volume":"33","author":"Folkmane","year":"2001","journal-title":"Transplantation Proceedings"},{"issue":"2","key":"10.1002\/14651858.CD003897.pub3-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/S0041-1345(01)02845-7","article-title":"Results of renal transplantation with different immunosuppressive regimens","volume":"34","author":"Folkmane","year":"2002","journal-title":"Transplantation Proceedings"},{"key":"10.1002\/14651858.CD003897.pub3-BIB0092|cit92","unstructured":"Folkmane I Chapenko S Murovska M Rosental R Low rate of acute rejection and cytomegalovirus infection in renal transplant recipients with basiliximab [abstract no:1037] A Transplant Odyssey; 2001 Aug 20-23; Istanbul, Turkey 2001"},{"key":"10.1002\/14651858.CD003897.pub3-BIB0093|cit93","unstructured":"Garcia R Hanzawa NM Machado PGP Moreira SR Prismich G Felipe CR A calcineurin inhibitor-free regimen for low risk kidney transplant recipients [abstract no:2379] XIXth International Congress of the Transplantation Society; 2002 Aug 25-30; Miami, FL 2002"},{"key":"10.1002\/14651858.CD003897.pub3-BIB0094|cit94","unstructured":"Gelens M Christiaans M Hooff JV Calcineurin-free immunosuppression and limited steroid exposure in renal transplantation [abstract] 3rd International Congress on Immunosuppression; 2004 Dec 8-11; San Diego (CA) 2004"},{"issue":"9","key":"10.1002\/14651858.CD003897.pub3-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1097\/01.tp.0000232688.76018.19","article-title":"High rejection rate during calcineurin inhibitor-free and early steroid withdrawal immunosuppression in renal transplantation","volume":"82","author":"Gelens","year":"2006","journal-title":"Transplantation"},{"issue":"10","key":"10.1002\/14651858.CD003897.pub3-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1016\/j.transproceed.2007.04.032","article-title":"Basiliximab versus daclizumab combined with triple immunosuppression in deceased donor renal graft recipients","volume":"39","author":"Grego","year":"2007","journal-title":"Transplantation Proceedings"},{"issue":"Abstracts","key":"10.1002\/14651858.CD003897.pub3-BIB0097|cit97","first-page":"223A","article-title":"Basiliximab versus daclizumab for prevention of acute renal allograft rejection [abstract no: TH-PO544]","volume":"17","author":"Grego","year":"2006","journal-title":"Journal of the American Society of Nephrology"},{"issue":"7","key":"10.1002\/14651858.CD003897.pub3-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1111\/j.1600-6143.2006.01367.x","article-title":"A prospective, randomized, multicenter trial of tacrolimus-based therapy with or without basiliximab in pediatric renal transplantation","volume":"6","author":"Grenda","year":"2006","journal-title":"American Journal of Transplantation"},{"key":"10.1002\/14651858.CD003897.pub3-BIB0099|cit99","unstructured":"Grenda R Watson A Vondrak K Webb NJ Beattie J Paediatric Tacrolimus Study Group Tacrolimus triple therapy with or without monoclonal antibody administration: a multicentre, randomised study in paediatric kidney transplantation [abstract] 3rd International Congress on Immunosuppression; 2004 Dec 8-11; San Diego (CA) 2004"},{"issue":"Suppl 11","key":"10.1002\/14651858.CD003897.pub3-BIB0100|cit100","first-page":"401","article-title":"Tacrolimus triple therapy with or without monoclonal antibody administration: a multicentre, randomized study in pediatric kidney transplantation [abstract no: 964]","volume":"5","author":"Vondrak","year":"2005","journal-title":"American Journal of Transplantation"},{"issue":"9","key":"10.1002\/14651858.CD003897.pub3-BIB0101|cit101","first-page":"1446","article-title":"Multicentre randomized prospective trial of tacrolimus, azathioprine and prednisolone with or without basiliximab; two year follow-up data [abstract no: 121 (FC)]","volume":"22","author":"Webb","year":"2007","journal-title":"Paediatric Nephrology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD003897.pub3-BIB0102|cit102","first-page":"215","article-title":"12 month results of a multicenter, randomized trial comparing three induction agents (Alemtuzumab, Thymoglobulin and Basiliximab) with tacrolimus, mycophenolate mofetil and a rapid steroid withdrawal in renal transplantation [abstract no: 135]","volume":"8","author":"Hanaway","year":"2008","journal-title":"American Journal of Transplantation"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD003897.pub3-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1097\/01.tp.0000332232.05273.4f","article-title":"Immune cell activation comparing three induction agents (alemtuzumab, thymoglobulin and basiliximab) with tacrolimus, mycophenolate mofetil and a rapid steroid withdrawal in renal transplantation [abstract no: 553]","volume":"86","author":"Holman","year":"2008","journal-title":"Transplantation"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD003897.pub3-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1097\/01.tp.0000331765.03512.81","article-title":"12 month results of a multicenter, randomized trial comparing three induction agents (alemtuzumab, thymoglobulin and basiliximab) with tacrolimus, mycophenolate mofetil and a rapid steroid withdrawal in renal transplantation [abstract no: 876]","volume":"86","author":"Woodle","year":"2008","journal-title":"Transplantation"},{"issue":"6","key":"10.1002\/14651858.CD003897.pub3-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1097\/01.tp.0000282872.17024.b7","article-title":"Randomized controlled study comparing reduced calcineurin inhibitors exposure versus standard cyclosporine-based immunosuppression","volume":"84","author":"Hernandez","year":"2007","journal-title":"Transplantation"},{"issue":"2","key":"10.1002\/14651858.CD003897.pub3-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1097\/00007890-199401001-00008","article-title":"Prevention of acute rejection episodes with an anti-interleukin 2 receptor monoclonal antibody. II. Results after a second kidney transplantation","volume":"57","author":"Hourmant","year":"1994","journal-title":"Transplantation"},{"issue":"5","key":"10.1002\/14651858.CD003897.pub3-BIB0107|cit107","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1016\/j.transproceed.2006.11.016","article-title":"A single-dose daclizumab induction protocol in renal allograft recipients: a Chinese single center experience","volume":"39","author":"Ji","year":"2007","journal-title":"Transplantation Proceedings"},{"key":"10.1002\/14651858.CD003897.pub3-BIB0108|cit108","doi-asserted-by":"crossref","unstructured":"Hall M Kovarik J Gerbeau C Schmidt AG Influence of the duration of IL-2 receptor (IL-2R) blockade on the incidence of acute rejection episodes in renal transplantation [abstract] XVII World Congress of the Transplantation Society; 1998 Jul 12-17; Montreal, Canada 1998","DOI":"10.1097\/00007890-199806270-00727"},{"issue":"2","key":"10.1002\/14651858.CD003897.pub3-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1097\/00007890-199901270-00016","article-title":"Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2-receptor monoclonal antibody. United States Simulect Renal Study Group","volume":"67","author":"Kahan","year":"1999","journal-title":"Transplantation"},{"key":"10.1002\/14651858.CD003897.pub3-BIB0112|cit110","unstructured":"Kahan BD Rajagopalan PR Hall ML Reduction of acute cellular rejection in renal allograft patients with basiliximab (Simulect) 16th Annual Meeting. American Society of Transplant Physicians (ASTP); 1997 May 10-14; Chicago (ILL) 1997 260"},{"issue":"12","key":"10.1002\/14651858.CD003897.pub3-BIB0110|cit111","doi-asserted-by":"crossref","first-page":"S189","DOI":"10.1097\/00007890-199806270-00767","article-title":"Basiliximab (Simulect) is efficacious in reducing the incidence of acute rejection episodes in renal allograft patients: results at 12 months [abstract]","volume":"65","author":"Kahan","year":"1998","journal-title":"Transplantation"},{"issue":"8","key":"10.1002\/14651858.CD003897.pub3-BIB0111|cit112","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1097\/00007890-199810270-00031","article-title":"Basiliximab (Simulect) is efficacious in reducing the incidence of acute rejection episodes in renal allograft patients: results at 12 months [abstract]","volume":"66","author":"Kahan","year":"1998","journal-title":"Transplantation"},{"key":"10.1002\/14651858.CD003897.pub3-BIB0113|cit113","unstructured":"Keown P Balshaw R Kalo Z Khorasheh S Matthisson M Economic analysis of basiliximab (Simulect) in renal transplantation A Transplant Odyssey; 2001 Aug 20-23; Istanbul, Turkey 2001"},{"issue":"9","key":"10.1002\/14651858.CD003897.pub3-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1097\/00007890-199911150-00012","article-title":"Population pharmacokinetics and exposure-response relationships for basiliximab in kidney transplantation. The U.S. Simulect Renal Transplant Study Group","volume":"68","author":"Kovarik","year":"1999","journal-title":"Transplantation"},{"issue":"12","key":"10.1002\/14651858.CD003897.pub3-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"S179","DOI":"10.1097\/00007890-199806270-00727","article-title":"Influence of the duration of IL-2 receptor (IL-2R) blockade on the incidence of acute rejection episodes in renal transplantation [abstract]","volume":"65","author":"Kovarik","year":"1998","journal-title":"Transplantation"},{"issue":"5","key":"10.1002\/14651858.CD003897.pub3-BIB0116|cit116","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1034\/j.1399-0012.2000.140506.x","article-title":"A prospective economic evaluation of basiliximab (Simulect) therapy following renal transplantation","volume":"14","author":"Lorber","year":"2000","journal-title":"Clinical Transplantation"},{"issue":"1-2","key":"10.1002\/14651858.CD003897.pub3-BIB0119|cit117","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1016\/S0041-1345(98)02094-6","article-title":"Simulect (basiliximab) reduces acute cellular rejection in renal allografts from cadaveric and living donors","volume":"31","author":"Mulloy","year":"1999","journal-title":"Transplantation Proceedings"},{"issue":"8","key":"10.1002\/14651858.CD003897.pub3-BIB0117|cit118","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1097\/00007890-199810270-00032","article-title":"Basiliximab (Simulect) reduces acute cellular rejection in renal allografts from cadaveric and living donors [abstract]","volume":"66","author":"Mulloy","year":"1998","journal-title":"Transplantation"},{"issue":"12","key":"10.1002\/14651858.CD003897.pub3-BIB0118|cit119","doi-asserted-by":"crossref","first-page":"S190","DOI":"10.1097\/00007890-199806270-00768","article-title":"Basiliximab (Simulect) reduces acute cellular rejection in renal allografts from cadaveric and living donors [abstract]","volume":"65","author":"Mulloy","year":"1998","journal-title":"Transplantation"},{"key":"10.1002\/14651858.CD003897.pub3-BIB0120|cit120","doi-asserted-by":"crossref","unstructured":"Nashan B Thistlethwaite R Schmidt AG Hall M Chodoff L Global Simulect Study Group Reduced acute rejection and superior one-year renal allograft survival with basiliximab (Simulect) in patients with diabetes mellitus [abstract] XVII World Congress of the Transplantation Society; 1998 Jul 12-17; Montreal, Canada 1998","DOI":"10.1097\/00007890-199806270-00726"},{"issue":"12","key":"10.1002\/14651858.CD003897.pub3-BIB0121|cit121","doi-asserted-by":"crossref","first-page":"S179","DOI":"10.1097\/00007890-199806270-00726","article-title":"Reduced acute rejection and superior one-year renal allograft survival with basiliximab (Simulect) in patients with diabetes mellitus [abstract]","volume":"65","author":"Nashan","year":"1998","journal-title":"Transplantation"},{"key":"10.1002\/14651858.CD003897.pub3-BIB0122|cit122","unstructured":"Soulillou JP Kahan BD Hall ML Schmidt AG CHIB 352\/201 Simulect Study Groups Basiliximab (Simulect) significantly reduced the incidence of acute rejection episodes in renal allograft patients: pooled data US\/Europe\/Canada Studies [abstract] XVII World Congress of the Transplantation Society; 1998 Jul 12-17; Montreal, Canada 1998"},{"issue":"5","key":"10.1002\/14651858.CD003897.pub3-BIB0123|cit123","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1097\/00007890-200009150-00013","article-title":"Reduced acute rejection and superior 1-year renal allograft survival with basiliximab in patients with diabetes mellitus. The Global Simulect Study Group","volume":"70","author":"Thistlethwaite","year":"2000","journal-title":"Transplantation"},{"issue":"Suppl 5","key":"10.1002\/14651858.CD003897.pub3-BIB0124|cit124","first-page":"212","article-title":"Pilot randomized prospective study of dual vs triple immunosuppression in older renal transplant recipients [abstract]","volume":"3","author":"Kaplan","year":"2003","journal-title":"American Journal of Transplantation"},{"issue":"Sept","key":"10.1002\/14651858.CD003897.pub3-BIB0125|cit125","first-page":"694A","article-title":"Comparison of two IL-2 receptor blockers in decreasing the incidence of acute rejection in early post-transplant time in renal transplant recipients [abstract]","volume":"11","author":"Khan","year":"2000","journal-title":"Journal of the American Society of Nephrology"},{"issue":"4","key":"10.1002\/14651858.CD003897.pub3-BIB0126|cit126","first-page":"21","article-title":"ATG-Fresenius or daclizumab induction therapy in immunologically high risk kidney recipients: a prospective randomized pilot trial","volume":"13","author":"Kim","year":"2008","journal-title":"Annals of Transplantation"},{"issue":"5 Suppl 2","key":"10.1002\/14651858.CD003897.pub3-BIB0127|cit127","first-page":"54","article-title":"Prophylactic use of monoclonal anti-IL-2 receptor antibody in cadaveric renal transplantation","volume":"14","author":"Carpenter","year":"1989","journal-title":"American Journal of Kidney Diseases"},{"issue":"1 Pt 2","key":"10.1002\/14651858.CD003897.pub3-BIB0128|cit128","first-page":"1766","article-title":"Early experience with anti-Tac in clinical renal transplantation","volume":"21","author":"Kirkman","year":"1989","journal-title":"Transplantation Proceedings"},{"key":"10.1002\/14651858.CD003897.pub3-BIB0129|cit129","first-page":"231","article-title":"In vivo anti-interleukin-2 receptor (anti-Tac) therapy is immunosuppressive, but not tolerogenic","volume":"102","author":"Ramos","year":"1989","journal-title":"Transactions of the Association of American Physicians"},{"issue":"3","key":"10.1002\/14651858.CD003897.pub3-BIB0130|cit130","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1097\/00007890-198909000-00012","article-title":"Differential IL-2 receptor expression in renal allograft recipients treated with an anti-IL-2-receptor antibody","volume":"48","author":"Ramos","year":"1989","journal-title":"Transplantation"},{"issue":"5 Suppl 2","key":"10.1002\/14651858.CD003897.pub3-BIB0131|cit131","first-page":"54","article-title":"Prophylactic use of monoclonal anti-IL-2 receptor antibody in cadaveric renal transplantation","volume":"14","author":"Carpenter","year":"1989","journal-title":"American Journal of Kidney Diseases"},{"issue":"1","key":"10.1002\/14651858.CD003897.pub3-BIB0132|cit132","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1097\/00007890-199101000-00016","article-title":"A randomized prospective trial of anti-Tac monoclonal antibody in human renal transplantation","volume":"51","author":"Kirkman","year":"1991","journal-title":"Transplantation"},{"issue":"1 Pt 2","key":"10.1002\/14651858.CD003897.pub3-BIB0133|cit133","first-page":"1066","article-title":"A randomized prospective trial of anti-Tac monoclonal antibody in human renal transplantation","volume":"23","author":"Kirkman","year":"1991","journal-title":"Transplantation Proceedings"},{"key":"10.1002\/14651858.CD003897.pub3-BIB0134|cit134","first-page":"231","article-title":"In vivo anti-interleukin-2 receptor (anti-Tac) therapy is immunosuppressive, but not tolerogenic","volume":"102","author":"Ramos","year":"1989","journal-title":"Transactions of the Association of American Physicians"},{"issue":"3","key":"10.1002\/14651858.CD003897.pub3-BIB0135|cit135","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1097\/00007890-198909000-00012","article-title":"Differential IL-2 receptor expression in renal allograft recipients treated with an anti-IL-2-receptor antibody","volume":"48","author":"Ramos","year":"1989","journal-title":"Transplantation"},{"issue":"10","key":"10.1002\/14651858.CD003897.pub3-BIB0136|cit136","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1111\/j.1432-2277.2006.00357.x","article-title":"Long-term results (10 years) of a prospective trial comparing Lo-tact-1 monoclonal antibody and anti-thymocyte globulin induction therapy in kidney transplantation","volume":"19","author":"Beaudreuil","year":"2006","journal-title":"Transplant International"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD003897.pub3-BIB0137|cit137","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1097\/00007890-200407271-01256","article-title":"Long term follow-up (10 years) of a prospective trial assay comparing lo-tact-1 antibody versus anti-thymocyte globulin induction therapy in kidney transplantation [abstract]","volume":"78","author":"Beaudreuil","year":"2004","journal-title":"Transplantation"},{"issue":"1 Pt 1","key":"10.1002\/14651858.CD003897.pub3-BIB0138|cit138","first-page":"817","article-title":"Prophylactic use of the anti-IL-2 receptor monoclonal antibody LO-Tact-1 in cadaveric renal transplantation: results of a randomized study","volume":"25","author":"Kriaa","year":"1993","journal-title":"Transplantation Proceedings"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD003897.pub3-BIB0139|cit139","first-page":"171","article-title":"Value of one month protocol biopsies combined with a molecular analysis in predicting efficacy of rapid steroid withdrawal after renal transplantation [abstract]","volume":"2","author":"Fa","year":"2002","journal-title":"American Journal of Transplantation"},{"issue":"Suppl 5","key":"10.1002\/14651858.CD003897.pub3-BIB0140|cit140","first-page":"480","article-title":"The predictive value of subclinical rejection in a steroid free immunosuppressive regimen [abstract]","volume":"3","author":"Fa","year":"2003","journal-title":"American Journal of Transplantation"},{"issue":"6","key":"10.1002\/14651858.CD003897.pub3-BIB0141|cit141","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1097\/01.tp.0000203558.34739.c6","article-title":"Safety and efficacy of steroid withdrawal two days after kidney transplantation: analysis of results at three years","volume":"81","author":"Kumar","year":"2006","journal-title":"Transplantation"},{"key":"10.1002\/14651858.CD003897.pub3-BIB0142|cit142","unstructured":"Kumar MSA Hahn J Adams C Fa K Fyfe B Damask A Steroid avoidance (SA) in kidney transplant recipients treated with simulect (BMAB), neoral (CSA) and cellcept (MMF) - a randomized prospective controlled clinical trial [abstract no:2440] XIXth International Congress of the Transplantation Society; 2002 Aug 25-30; Miami, FL 2002"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD003897.pub3-BIB0143|cit143","first-page":"393","article-title":"Steroid avoidance (SA) in kidney transplant recipients treated with simulect (BMAB), neoral (CSA) and cellcept (MMF) - a randomized prospective controlled clinical trial [abstract]","volume":"2","author":"Kumar","year":"2002","journal-title":"American Journal of Transplantation"},{"issue":"1","key":"10.1002\/14651858.CD003897.pub3-BIB0144|cit144","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/j.1399-0012.2004.00298.x","article-title":"Steroid avoidance in renal transplantation using basiliximab induction, cyclosporine-based immunosuppression and protocol biopsies","volume":"19","author":"Kumar","year":"2005","journal-title":"Clinical Transplantation"},{"key":"10.1002\/14651858.CD003897.pub3-BIB0145|cit145","unstructured":"Kyllonen L Eklund B Matinlauri I Salmela K Induction with single bolus ATG or basiliximab in cadaveric kidney transplantation with cyclosporin immunosuppression [abstract] XIXth International Congress of the Transplantation Society, Miami, Florida"},{"issue":"4 Suppl","key":"10.1002\/14651858.CD003897.pub3-BIB0146|cit146","first-page":"466","article-title":"Induction with single bolus ATGor basiliximab in cadaveric kidney transplantation with cyclosporin immunosuppression [abstract no: 2330]","volume":"74","author":"Kyllonen","year":"2002","journal-title":"Transplantation"},{"issue":"1","key":"10.1002\/14651858.CD003897.pub3-BIB0147|cit147","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1097\/01.tp.0000268084.64888.f3","article-title":"Single bolus antithymocyte globulin versus basiliximab induction in kidney transplantation with cyclosporine triple immunosuppression: efficacy and safety","volume":"84","author":"Kyllonen","year":"2007","journal-title":"Transplantation"},{"issue":"2","key":"10.1002\/14651858.CD003897.pub3-BIB0148|cit148","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1097\/01.TP.0000128190.08238.A1","article-title":"Weak humoral posttransplant alloresponse after a well-HLA-matched cadaveric kidney transplantation","volume":"78","author":"Matinlauri","year":"2004","journal-title":"Transplantation"},{"issue":"12","key":"10.1002\/14651858.CD003897.pub3-BIB0149|cit149","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1097\/01.tp.0000188175.66835.c6","article-title":"Serum sCD30 in monitoring of alloresponse in well HLA-matched cadaveric kidney transplantations","volume":"80","author":"Matinlauri","year":"2005","journal-title":"Transplantation"},{"issue":"9","key":"10.1002\/14651858.CD003897.pub3-BIB0150|cit150","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1111\/j.1600-6143.2005.00994.x","article-title":"Activated protein C reduces graft neutrophil activation in clinical renal transplantation","volume":"5","author":"Turunen","year":"2005","journal-title":"American Journal of Transplantation"},{"issue":"12","key":"10.1002\/14651858.CD003897.pub3-BIB0151|cit151","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1097\/01.TP.0000122231.43653.CC","article-title":"Association of graft neutrophil sequestration with delayed graft function in clinical renal transplantation","volume":"77","author":"Turunen","year":"2004","journal-title":"Transplantation"},{"issue":"Suppl 8","key":"10.1002\/14651858.CD003897.pub3-BIB0152|cit152","first-page":"265","article-title":"Long-term effect of zenapax versus okt-3 prophylaxis in immunologically high-risk kidney transplant recipients [abstract]","volume":"4","author":"Lacha","year":"2004","journal-title":"American Journal of Transplantation"},{"issue":"3","key":"10.1002\/14651858.CD003897.pub3-BIB0154|cit153","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1016\/S0041-1345(01)01988-1","article-title":"Zenapax versus OKT-3 prophylaxis in immunologically high-risk kidney transplant recipients","volume":"33","author":"Lacha","year":"2001","journal-title":"Transplantation Proceedings"},{"issue":"8","key":"10.1002\/14651858.CD003897.pub3-BIB0153|cit154","doi-asserted-by":"crossref","first-page":"S158","DOI":"10.1097\/00007890-200004271-00174","article-title":"Zenapax versus OKT-3 prophylaxis in immunologically high-risk kidney transplant recipients [abstract]","volume":"69","author":"Lacha","year":"2000","journal-title":"Transplantation"},{"key":"10.1002\/14651858.CD003897.pub3-BIB0155|cit155","unstructured":"Lacha J Viklicky O Noskova L Kalanin J Striz I Vitko S Zenapax versus OKT-3 prophylaxis in immunologically high-risk kidney transplant recipients [abstract] XIXth International Congress of the Transplantation Society; 2002 Aug 25-30; Miami, FL 2002"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD003897.pub3-BIB0156|cit156","first-page":"725A","article-title":"Basiliximab (Simulect) is safe and effective in combination with neoral, steroids and cellcept for the prevention of acute rejection episodes in renal transplantation. Interim results of a double blind, randomized clinical trial [abstract]","volume":"10","author":"Davies","year":"1999","journal-title":"American Society of Nephrology"},{"issue":"8 Suppl","key":"10.1002\/14651858.CD003897.pub3-BIB0157|cit157","doi-asserted-by":"crossref","first-page":"S260","DOI":"10.1097\/00007890-200004271-00572","article-title":"Basiliximab (Simulect) is safe and effective in combination with triple therapy of neoral steroids and cellcept in renal transplant recipients [abstract]","volume":"69","author":"Lawen","year":"2000","journal-title":"Transplantation"},{"issue":"1","key":"10.1002\/14651858.CD003897.pub3-BIB0158|cit158","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1097\/00007890-200301150-00007","article-title":"Randomized double-blind study of immunoprophylaxis with basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody, in combination with mycophenolate mofetil-containing triple therapy in renal transplantation","volume":"75","author":"Lawen","year":"2003","journal-title":"Transplantation"},{"issue":"7","key":"10.1002\/14651858.CD003897.pub3-BIB0159|cit159","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1016\/j.transproceed.2006.06.133","article-title":"Long-term results of monoclonal anti-Il2-receptor antibody versus polyclonal antilymphocyte antibodies as induction therapy in renal transplantation","volume":"38","author":"Al Najjar","year":"2006","journal-title":"Transplantation Proceedings"},{"key":"10.1002\/14651858.CD003897.pub3-BIB0160|cit160","unstructured":"Brun C Al Najjar A Buchler M Le Pen C Lebranchu Y Lilliu H Cost-minimisation study comparing simulect versus thymoglobuline in renal transplant induction A Transplant Odyssey; 2001 Aug 20-23; Istanbul, Turkey 2001"},{"issue":"Suppl 8","key":"10.1002\/14651858.CD003897.pub3-BIB0161|cit161","first-page":"349","article-title":"Three year results of a randomized study comparing as induction treatment simulect\u00ae and thymoglobuline\u00ae. [abstract]","volume":"4","author":"Buchler","year":"2004","journal-title":"American Journal of Transplantation"},{"issue":"1","key":"10.1002\/14651858.CD003897.pub3-BIB0162|cit162","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1034\/j.1600-6143.2002.020109.x","article-title":"Immunoprophylaxis with basiliximab compared with antithymocyte globulin in renal transplant patients receiving MMF-containing triple therapy","volume":"2","author":"Lebranchu","year":"2002","journal-title":"American Journal of Transplantation"},{"key":"10.1002\/14651858.CD003897.pub3-BIB0163|cit163","unstructured":"Lebranchu Y Bridoux F Etienne I Buchler M Toupance O Le Meur Y A multicenter, randomized trial of Simulect versus thymoglobuline in renal transplantation [abstract no:1598] A Transplant Odyssey; 2001 Aug 20-23; Istanbul, Turkey 2001"},{"key":"10.1002\/14651858.CD003897.pub3-BIB0164|cit164","doi-asserted-by":"crossref","unstructured":"Lebranchu Y Bridoux F Lemeur Y Bouchoule I Lavaud S Lobbedez T A multicenter randomized trial of Simulect versus thymoglobuline in renal transplantation [abstract] XVIII International Congress of the Transplantation Society; 2000 Aug 27-Sept 1; Rome, Italy 2000","DOI":"10.1097\/00007890-200004271-00567"},{"issue":"8 Suppl","key":"10.1002\/14651858.CD003897.pub3-BIB0165|cit165","doi-asserted-by":"crossref","first-page":"S258","DOI":"10.1097\/00007890-200004271-00567","article-title":"A multicenter randomized trial of Simulect versus thymoglobuline in renal transplantation [abstract]","volume":"69","author":"Lebranchu","year":"2000","journal-title":"Transplantation"},{"issue":"7-8","key":"10.1002\/14651858.CD003897.pub3-BIB0166|cit166","doi-asserted-by":"crossref","first-page":"3197","DOI":"10.1016\/S0041-1345(01)02360-0","article-title":"Cost-minimization study comparing Simulect versus Thymoglobulin in renal transplant induction","volume":"33","author":"Lilliu","year":"2001","journal-title":"Transplantation Proceedings"},{"issue":"3","key":"10.1002\/14651858.CD003897.pub3-BIB0167|cit167","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/j.1399-0012.2004.00148.x","article-title":"Cost-minimization study comparing Simulect vs. Thymoglobulin in renal transplant induction","volume":"18","author":"Lilliu","year":"2004","journal-title":"Clinical Transplantation"},{"issue":"2","key":"10.1002\/14651858.CD003897.pub3-BIB0168|cit168","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1097\/00007890-200407271-01252","article-title":"The clinical study of two-dose basiliximab compared with two-dose daclizumab in renal transplantation [abstract]","volume":"78","author":"Lin","year":"2004","journal-title":"Transplantation"},{"issue":"3","key":"10.1002\/14651858.CD003897.pub3-BIB0169|cit169","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/j.1399-0012.2005.00488.x","article-title":"Two-dose basiliximab compared with two-dose daclizumab in renal transplantation: a clinical study","volume":"20","author":"Lin","year":"2006","journal-title":"Clinical Transplantation"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD003897.pub3-BIB0170|cit170","first-page":"182","article-title":"Effect of induction agent on cellular and humoral responses to renal transplants in sensitized patients [abstract no: 14]","volume":"8","author":"Leffell","year":"2008","journal-title":"American Journal of Transplantation"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD003897.pub3-BIB0171|cit171","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1097\/01.tp.0000332343.24572.0f","article-title":"Results of a randomized prospective study of induction therapy with daclizumab versus thymoglobulin among crossmatch positive renal transplant recipients [abstract no: 521]","volume":"86","author":"Locke","year":"2008","journal-title":"Transplantation"},{"issue":"5","key":"10.1002\/14651858.CD003897.pub3-BIB0172|cit172","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1016\/S0041-1345(03)00576-1","article-title":"Tacrolimus-basiliximab versus cyclosporine-basiliximab in renal transplantation \"de novo\": acute rejection and complications","volume":"35","author":"Martin","year":"2003","journal-title":"Transplantation Proceedings"},{"key":"10.1002\/14651858.CD003897.pub3-BIB0174|cit173","doi-asserted-by":"crossref","unstructured":"Matl I Bachleda P Lao M Michalsky R Navratil P Treska V Basiliximab (Simulect) can be administered safely and effectively by IV bolus in a single dose on day 1 post renal transplantation in patients receiving triple therapy with azathioprine [abstract no:1107] A Transplant Odyssey; 2001 Aug 20-23; Istanbul, Turkey 2001","DOI":"10.1016\/S0041-1345(01)02364-8"},{"issue":"1","key":"10.1002\/14651858.CD003897.pub3-BIB0173|cit174","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/j.1432-2277.2003.tb00222.x","article-title":"Safety and efficacy of an alternative basiliximab (Simulect) regimen after renal transplantation: administration of a single 40-mg dose on the first postoperative day in patients receiving triple therapy with azathioprine","volume":"16","author":"Matl","year":"2003","journal-title":"Transplant International"},{"issue":"7-8","key":"10.1002\/14651858.CD003897.pub3-BIB0175|cit175","doi-asserted-by":"crossref","first-page":"3205","DOI":"10.1016\/S0041-1345(01)02364-8","article-title":"Basiliximab can be administered safely and effectively in a single dose on day 1 postrenal transplantation in patients receiving triple therapy with azathioprine","volume":"33","author":"Matl","year":"2001","journal-title":"Transplantation Proceedings"},{"issue":"4","key":"10.1002\/14651858.CD003897.pub3-BIB0176|cit176","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1097\/01.TP.0000129812.68794.CC","article-title":"Sequential protocols using basiliximab versus antithymocyte globulins in renal-transplant patients receiving mycophenolate mofetil and steroids","volume":"78","author":"Mourad","year":"2004","journal-title":"Transplantation"},{"key":"10.1002\/14651858.CD003897.pub3-BIB0177|cit177","unstructured":"Mourad G Rostaing L Legendre C Lorho R Therver E Fares N Simulect versus thymoglobulin with delayed introduction of neoral in renal transplantation: three month results of a French multicenter randomized trial [abstract] XIXth International Congress of the Transplantation Society; 2002 Aug 25-30; Miami, FL 2002"},{"issue":"Suppl 5","key":"10.1002\/14651858.CD003897.pub3-BIB0178|cit178","first-page":"462","article-title":"A sequential protocol using simulect vs thymoglobulin in low immunological risk renal transplant recipients: six-month results of a French multicenter, randomized trial [abstract]","volume":"3","author":"Mourad","year":"2003","journal-title":"American Journal of Transplantation"},{"issue":"5","key":"10.1002\/14651858.CD003897.pub3-BIB0179|cit179","doi-asserted-by":"crossref","first-page":"2767","DOI":"10.1016\/S0041-1345(01)02184-4","article-title":"Induction immunosuppression with interleukin-2 receptor antibodies (basiliximab and daclizumab) in renal transplant recipients","volume":"33","author":"Nair","year":"2001","journal-title":"Transplantation Proceedings"},{"issue":"7","key":"10.1002\/14651858.CD003897.pub3-BIB0180|cit180","doi-asserted-by":"crossref","first-page":"2916","DOI":"10.1016\/S0041-1345(02)03487-5","article-title":"Bolus anti-thymocyte globulin induction in renal transplant recipients: a comparison with conventional ATG or anti-interleukin-2 receptor antibody induction","volume":"34","author":"Nampoory","year":"2002","journal-title":"Transplantation Proceedings"},{"issue":"Sept","key":"10.1002\/14651858.CD003897.pub3-BIB0181|cit181","first-page":"699A","article-title":"Induction immunosuppression with anti interleukin (IL-2) receptor antibodies and anti thymocyte globulin in renal transplantation - a comparative study [abstract]","volume":"11","author":"Nampoory","year":"2000","journal-title":"Journal of the American Society of Nephrology"},{"issue":"7","key":"10.1002\/14651858.CD003897.pub3-BIB0182|cit182","doi-asserted-by":"crossref","first-page":"S155","DOI":"10.1097\/00007890-199904150-00621","article-title":"The economic implications of the use of Basiliximab versus placebo for the control of acute cellular rejection in renal allograft recipients [abstract]","volume":"67","author":"Akehurst","year":"1999","journal-title":"Transplantation"},{"key":"10.1002\/14651858.CD003897.pub3-BIB0183|cit183","unstructured":"Breidenbach T Korn A Maibucher A Schlitt HJ Oldhafer KJ Kliem V Two years results of a clinical trial with basiliximab (Simulect) in renal transplantation [abstract] XVII World Congress of the Transplantation Society; 1998 Jul 12-17; Montreal, Canada 1998"},{"issue":"12","key":"10.1002\/14651858.CD003897.pub3-BIB0184|cit184","doi-asserted-by":"crossref","first-page":"S180","DOI":"10.1097\/00007890-199806270-00728","article-title":"Basiliximab (Simulect) reduces acute rejections, CMV infections and duration of hospital stay in renal allograft patients [abstract]","volume":"65","author":"Breidenbach","year":"1998","journal-title":"Transplantation"},{"key":"10.1002\/14651858.CD003897.pub3-BIB0185|cit185","unstructured":"Chilcott J Akehurst R Whitfield M Economics of Basiliximab (Simulect) in preventing acute rejection in renal transplantation [abstract no:1453] A Transplant Odyssey; 2001 Aug 20-23; Istanbul, Turkey 2001"},{"issue":"9-10","key":"10.1002\/14651858.CD003897.pub3-BIB0186|cit186","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1111\/j.1432-2277.2002.tb00204.x","article-title":"The economics of basiliximab (Simulect) in preventing acute rejection in renal transplantation","volume":"15","author":"Chilcott","year":"2002","journal-title":"Transplant International"},{"key":"10.1002\/14651858.CD003897.pub3-BIB0187|cit187","unstructured":"Keown P Balshaw R Kalo Z Khorasheh S Matthisson M Economic analysis of basiliximab (simulect) in renal transplantation [abstract] A Transplant Odyssey; 2001 Aug 20-23; Istanbul, Turkey 2001"},{"key":"10.1002\/14651858.CD003897.pub3-BIB0188|cit188","unstructured":"Keown PA Balshaw R Baladi JF International Simulect Study Group Canadian economic analysis of basiliximab (Simulect) in renal transplantation [abstract no: P1041] XVIII International Congress of the Transplantation Society; 2000 Aug 27-Sept 1; Rome, Italy 2000"},{"issue":"11","key":"10.1002\/14651858.CD003897.pub3-BIB0189|cit189","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1097\/00007890-200106150-00015","article-title":"Economic analysis of basiliximab in renal transplantation","volume":"71","author":"Keown","year":"2001","journal-title":"Transplantation"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD003897.pub3-BIB0190|cit190","first-page":"395","article-title":"Long term results of basiliximab in renal transplantation [abstract no:1020]","volume":"2","author":"Koch","year":"2002","journal-title":"American Journal of Transplantation"},{"issue":"1 Pt 1","key":"10.1002\/14651858.CD003897.pub3-BIB0191|cit191","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1034\/j.1399-0012.1999.t01-2-130105.x","article-title":"Screening for basiliximab exposure-response relationships in renal allotransplantation","volume":"13","author":"Kovarik","year":"1999","journal-title":"Clinical Transplantation"},{"issue":"9086","key":"10.1002\/14651858.CD003897.pub3-BIB0192|cit192","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1016\/S0140-6736(97)09278-7","article-title":"Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. CHIB 201 International Study Group. [erratum appears in Lancet 1997 Nov 15;350(9089):1484]","volume":"350","author":"Nashan","year":"1997","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD003897.pub3-BIB0193|cit193","unstructured":"Nashan B Moore R Schmidt AG Abeywickrama K Soulillou JP CHIB201 International Study Group Reduction of acute cellular rejection by basiliximab (simulect), in renal allograft recipients [abstract] 16th Annual Meeting. American Society of Transplant Physicians (ASTP); 1997 May 10-14; Chicago (ILL) 1997 261"},{"key":"10.1002\/14651858.CD003897.pub3-BIB0194|cit194","doi-asserted-by":"crossref","unstructured":"Nashan B Thistlethwaite R Schmidt AG Hall M Chodoff L Global Simulect Study Group Reduced acute rejection and superior one-year renal allograft survival with basiliximab (Simulect) in patients with diabetes mellitus [abstract] XVII World Congress of the Transplantation Society; 1998 Jul 12-17; Montreal, Canada 1998","DOI":"10.1097\/00007890-199806270-00726"},{"issue":"12","key":"10.1002\/14651858.CD003897.pub3-BIB0195|cit195","doi-asserted-by":"crossref","first-page":"S179","DOI":"10.1097\/00007890-199806270-00726","article-title":"Reduced acute rejection and superior one-year renal allograft survival with basiliximab (Simulect) in patients with diabetes mellitus [abstract]","volume":"65","author":"Nashan","year":"1998","journal-title":"Transplantation"},{"key":"10.1002\/14651858.CD003897.pub3-BIB0196|cit196","unstructured":"Soulillou JP Kahan BD Hall ML Schmidt AG CHIB 352\/201 Simulect Study Groups Basiliximab (Simulect) significantly reduced the incidence of acute rejection episodes in renal allograft patients: pooled data US\/Europe\/Canada Studies [abstract] XVII World Congress of the Transplantation Society; 1998 Jul 12-17; Montreal, Canada 1998"},{"issue":"5","key":"10.1002\/14651858.CD003897.pub3-BIB0197|cit197","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1097\/00007890-200009150-00013","article-title":"Reduced acute rejection and superior 1-year renal allograft survival with basiliximab in patients with diabetes mellitus. The Global Simulect Study Group","volume":"70","author":"Thistlethwaite","year":"2000","journal-title":"Transplantation"},{"issue":"6","key":"10.1002\/14651858.CD003897.pub3-BIB0198|cit198","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1681\/ASN.2008101037","article-title":"Daclizumab versus antithymocyte globulin in high-immunological-risk renal transplant recipients","volume":"20","author":"Noel","year":"2009","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD003897.pub3-BIB0199|cit199","first-page":"233","article-title":"Daclizumab versus thymoglobulin in renal transplant recipients with a high immunological risk: a French and Belgian prospective randomized trial [abstract no: 331]","volume":"7","author":"Noel","year":"2007","journal-title":"American Journal of Transplantation"},{"issue":"10","key":"10.1002\/14651858.CD003897.pub3-BIB0200|cit200","first-page":"1574","article-title":"Pharmacokinetics and immunodynamics of basiliximab in pediatric renal transplant recipients under CsA, MMF and corticosteroids [abstract no: COD. PP 210]","volume":"21","author":"Hocker","year":"2006","journal-title":"Pediatric Nephrology"},{"issue":"9","key":"10.1002\/14651858.CD003897.pub3-BIB0201|cit201","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1097\/TP.0b013e318188ae18","article-title":"Pharmacokinetics and immunodynamics of basiliximab in pediatric renal transplant recipients on mycophenolate mofetil comedication","volume":"86","author":"Hocker","year":"2008","journal-title":"Transplantation"},{"issue":"9","key":"10.1002\/14651858.CD003897.pub3-BIB0202|cit202","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1097\/TP.0b013e318188af15","article-title":"Efficacy and safety of basiliximab in pediatric renal transplant patients receiving cyclosporine, mycophenolate mofetil, and steroids","volume":"86","author":"Offner","year":"2008","journal-title":"Transplantation"},{"issue":"10","key":"10.1002\/14651858.CD003897.pub3-BIB0203|cit203","first-page":"1513","article-title":"A multicenter, placebo-controlled trial evaluating the efficacy and safety of Basiliximab (Simulect) in combination with CsA, MMF and steroids in pediatric renal allograft recipients: 12 months results [abstract no: COD. OP 25]","volume":"21","author":"T\u00f6nshoff","year":"2006","journal-title":"Pediatric Nephrology"},{"issue":"Abstracts Issue","key":"10.1002\/14651858.CD003897.pub3-BIB0204|cit204","first-page":"679A","article-title":"Basiliximab as induction therapy in pediatric renal transplantation: 5 year results [abstract no: SA-PO2534]","volume":"19","author":"Zimmerhackl","year":"2008","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Abstracts","key":"10.1002\/14651858.CD003897.pub3-BIB0205|cit205","first-page":"671A","article-title":"First multicenter, placebo controlled trial of basiliximab (Simulect) in pediatric renal allograft recipients: efficacy results including a 6-month biopsy (for the pediatric simulect\u00ae study group) [abstract no: SA-PO451]","volume":"17","author":"Zimmerhackl","year":"2006","journal-title":"Journal of the American Society of Nephrology"},{"issue":"3","key":"10.1002\/14651858.CD003897.pub3-BIB0206|cit206","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1097\/01.TP.0000151006.86197.76","article-title":"Multicenter, randomized study of the effectiveness of basiliximab in avoiding addition of steroids to cyclosporine a monotherapy in renal transplant recipients","volume":"79","author":"Parrott","year":"2005","journal-title":"Transplantation"},{"issue":"Suppl 8","key":"10.1002\/14651858.CD003897.pub3-BIB0207|cit207","first-page":"350","article-title":"Basiliximab (simulect) with ciclosporin (neoral) as a strategy for steroid avoidance in renal transplantation. [abstract]","volume":"4","author":"Parrott","year":"2004","journal-title":"American Journal of Transplantation"},{"issue":"2","key":"10.1002\/14651858.CD003897.pub3-BIB0208|cit208","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s11255-006-0054-x","article-title":"Correlation between oxidative stress and immunosuppressive therapy in renal transplant recipients with an uneventful postoperative course and stable renal function","volume":"38","author":"Perrea","year":"2006","journal-title":"International Urology & Nephrology"},{"key":"10.1002\/14651858.CD003897.pub3-BIB0209|cit209","unstructured":"Kirkman RL Vincenti F Pescovitz MD Bumgardner GL Gaston RS Light SE A phase I\/II randomized, double blind, placebo controlled study of zenapax in combination with cellcept, neoral, and steroids. [abstract] 16th Annual Meeting. American Society of Transplant Physicians (ASTP); 1997 May 10-14; Chicago (ILL) 1997 260"},{"issue":"6","key":"10.1002\/14651858.CD003897.pub3-BIB0210|cit210","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1046\/j.1399-0012.2003.00079.x","article-title":"Pharmacokinetics of daclizumab and mycophenolate mofetil with cyclosporine and steroids in renal transplantation","volume":"17","author":"Pescovitz","year":"2003","journal-title":"Clinical Transplantation"},{"issue":"Suppl 11","key":"10.1002\/14651858.CD003897.pub3-BIB0211|cit211","first-page":"188","article-title":"Long term results of a prospective randomized study comparing OKT3 and a truncated daclizumab regimen as induction for marginal kidneys at high risk for delayed graft function [abstract no: 126]","volume":"5","author":"Philosophe","year":"2005","journal-title":"American Journal of Transplantation"},{"key":"10.1002\/14651858.CD003897.pub3-BIB0212|cit212","unstructured":"Philosophe B Wiland AM Mann DL Farney AC Schweitzer EJ Colonna JO Prospective randomized study comparing OKT3 and a truncated daclizumab regimen as induction for marginal kidneys at high risk for delayed graft function [abstract no:2063] XIXth International Congress of the Transplantation Society; 2002 Aug 25-30; Miami, FL 2002"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD003897.pub3-BIB0213|cit213","first-page":"239","article-title":"Prospective randomized study comparing OKT3 and a truncated daclizumab regimen as induction for marginal kidneys at high risk for delayed graft function [abstract no:402]","volume":"2","author":"Philosophe","year":"2002","journal-title":"American Journal of Transplantation"},{"key":"10.1002\/14651858.CD003897.pub3-BIB0214|cit214","unstructured":"Coppelli A Buonomo O Iaria G Pisani F Pollicita S Rizzello A Preliminary results of a prospective randomized study of basiliximab and steroid withdrawal in kidney transplantation [abstract no:1617] A Transplant Odyssey; 2001 Aug 20-23; Istanbul, Turkey 2001"},{"issue":"1-2","key":"10.1002\/14651858.CD003897.pub3-BIB0215|cit215","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1016\/S0041-1345(00)02778-0","article-title":"Preliminary results of a prospective randomized study of basiliximab in kidney transplantation","volume":"33","author":"Pisani","year":"2001","journal-title":"Transplantation Proceedings"},{"key":"10.1002\/14651858.CD003897.pub3-BIB0216|cit216","article-title":"Economics of basiliximab (Simulect) in preventing acute rejection in renal transplantation","author":"Chilcott","year":"2001","journal-title":"ISOT"},{"issue":"2","key":"10.1002\/14651858.CD003897.pub3-BIB0217|cit217","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1034\/j.1399-0012.2001.150208.x","article-title":"Differential influence of azathioprine and mycophenolate mofetil on the disposition of basiliximab in renal transplant patients","volume":"15","author":"Kovarik","year":"2001","journal-title":"Clinical Transplantation"},{"issue":"7","key":"10.1002\/14651858.CD003897.pub3-BIB0218|cit218","doi-asserted-by":"crossref","first-page":"S158","DOI":"10.1097\/00007890-199904150-00632","article-title":"A multicenter, double blind, placebo controlled study of basiliximab (simulect) in combination with triple therapy including azathioprine for the prevention of acute rejection episodes in renal allograft patients [abstract]","volume":"67","author":"Ponticelli","year":"1999","journal-title":"Transplantation"},{"issue":"8 Suppl","key":"10.1002\/14651858.CD003897.pub3-BIB0219|cit219","doi-asserted-by":"crossref","first-page":"S156","DOI":"10.1097\/00007890-200004271-00166","article-title":"Basiliximab (Simulect) significantly reduces the incidence of acute rejection in renal transplant patients receiving triple therapy with azathioprine [abstract]","volume":"69","author":"Ponticelli","year":"2000","journal-title":"Transplantation"},{"key":"10.1002\/14651858.CD003897.pub3-BIB0220|cit220","doi-asserted-by":"crossref","unstructured":"Ponticelli C Yussim A Cambi V Legendre C Rizzo G Salvadori M Basiliximab (Simulect) significantly reduces the incidence of acute rejection in renal transplant patients receiving a triple therapy with azathioprine [abstract] International Congress of the Transplantation Society; 2000 Aug 27-Sept 1; Rome, Italy 2000","DOI":"10.1097\/00007890-200004271-00166"},{"issue":"7","key":"10.1002\/14651858.CD003897.pub3-BIB0221|cit221","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1097\/00007890-200110150-00014","article-title":"A randomized, double-blind trial of basiliximab immunoprophylaxis plus triple therapy in kidney transplant recipients","volume":"72","author":"Ponticelli","year":"2001","journal-title":"Transplantation"},{"key":"10.1002\/14651858.CD003897.pub3-BIB0222|cit222","doi-asserted-by":"crossref","unstructured":"Ponticelli C Yussim A Cambi V Legendre C Rizzo G Salvadori M Basiliximab (Simulect) significantly reduces the incidence of acute rejection in renal transplant patients receiving a triple therapy with azathioprine [abstract no:0114] XVIII International Congress of the Transplantation Society; 2000 Aug 27-Sept 1; Rome, Italy 2000","DOI":"10.1097\/00007890-200004271-00166"},{"issue":"1-2","key":"10.1002\/14651858.CD003897.pub3-BIB0223|cit223","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/S0041-1345(00)02307-1","article-title":"Basiliximab significantly reduces acute rejection in renal transplant patients given triple therapy with azathioprine","volume":"33","author":"Ponticelli","year":"2001","journal-title":"Transplantation Proceedings"},{"key":"10.1002\/14651858.CD003897.pub3-BIB0226|cit224","unstructured":"Walters SJ Economics of basiliximab (Simulect) in preventing acute rejection in renal transplantation [abstract no:441] Proceedings.10th ESOT & 12th ETCO Congress; 2001 Oct 6 - 11; Lisboa, Portugal 2001"},{"issue":"2","key":"10.1002\/14651858.CD003897.pub3-BIB0224|cit225","doi-asserted-by":"crossref","first-page":"129","DOI":"10.2165\/00019053-200321020-00005","article-title":"Economic implications of the use of basiliximab in addition to triple immunosuppressive therapy in renal allograft recipients: a UK perspective","volume":"21","author":"Walters","year":"2003","journal-title":"Pharmacoeconomics"},{"issue":"7-8","key":"10.1002\/14651858.CD003897.pub3-BIB0225|cit226","doi-asserted-by":"crossref","first-page":"3187","DOI":"10.1016\/S0041-1345(01)02356-9","article-title":"Pharmacoeconomic evaluation of Simulect prophylaxis in renal transplant recipients","volume":"33","author":"Walters","year":"2001 Nov","journal-title":"Transplantation Proceedings"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD003897.pub3-BIB0227|cit227","first-page":"494","article-title":"Zenapax versus ALG prophylaxis in immunologically high-risk group of renal allograft recipients [abstract]","volume":"18","author":"Pourfarziani","year":"2003","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"1","key":"10.1002\/14651858.CD003897.pub3-BIB0228|cit228","first-page":"69","article-title":"Zenapax versus anti-lymphocyte globulin prophylaxis in immunologically high-risk group of renal allograft recipients","volume":"12","author":"Pourfarziani","year":"2007","journal-title":"Kowsar Medical Journal"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD003897.pub3-BIB0229|cit229","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1097\/00007890-200407271-00731","article-title":"Antilymphocyte therapy in kidney transplantation: a prospective randomized trial of full-dose rabbit anti-human thymocyte globulin (ratg) versus low-dose RATG and basiliximab. [abstract]","volume":"78","author":"Codreanu","year":"2004","journal-title":"Transplantation"},{"issue":"3","key":"10.1002\/14651858.CD003897.pub3-BIB0230|cit230","doi-asserted-by":"crossref","first-page":"546","DOI":"10.2215\/CJN.01841105","article-title":"Basiliximab combined with low-dose rabbit anti-human thymocyte globulin: A possible further step toward effective and minimally toxic T cell-targeted therapy in kidney transplantation","volume":"1","author":"Ruggenenti","year":"2006","journal-title":"Clinical Journal of the American Society of Nephrology - CJASN"},{"key":"10.1002\/14651858.CD003897.pub3-BIB0231|cit231","unstructured":"Boggi U Arisi L Valente U La Greca G Calconi G Donati D Basiliximab facilitates steroid withdrawal after primary kidney transplantation: results of a placebo-controlled study [abstract] XIXth International Congress of the Transplantation Society; 2002 Aug 25-30; Miami, FL 2002"},{"key":"10.1002\/14651858.CD003897.pub3-BIB0232|cit232","unstructured":"Sandrini S Arisi L Rizzo G Valente U La Greca G Calconi G Simulect facilitates steroid withdrawal after renal transplantation: results of an Italian, multicentre, placebo-controlled study [abstract] 5th International Conference on New Trends in Clinical and Experimental Immunosuppression; 2002 Feb 7-10; Geneva, Switzerland 2002"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD003897.pub3-BIB0233|cit233","first-page":"172","article-title":"Basiliximab facilitates steroid withdrawal after renal transplantation: results of an Italian, multicentre, placebo-controlled study (Swiss study) [abstract]","volume":"2","author":"Sandrini","year":"2002","journal-title":"American Journal of Transplantation"},{"issue":"3","key":"10.1002\/14651858.CD003897.pub3-BIB0234|cit234","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1159\/000085892","article-title":"Long-term evaluation of basiliximab induction therapy in live donor kidney transplantation: a five-year prospective randomized study","volume":"25","author":"Sheashaa","year":"2005","journal-title":"American Journal of Nephrology"},{"issue":"Suppl 5","key":"10.1002\/14651858.CD003897.pub3-BIB0235|cit235","first-page":"v161","article-title":"Basiliximab reduces the incidence of acute cellular rejection in live related donor kidney transplantation, results of five years prospective randomized trial [abstract no:SP425]","volume":"20","author":"Sheashaa","year":"2005","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"5","key":"10.1002\/14651858.CD003897.pub3-BIB0236|cit236","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1007\/s10157-008-0044-7","article-title":"Basiliximab induction therapy for live donor kidney transplantation: a long-term follow-up of prospective randomized controlled study","volume":"12","author":"Sheashaa","year":"2008","journal-title":"Clinical & Experimental Nephrology"},{"issue":"3","key":"10.1002\/14651858.CD003897.pub3-BIB0237|cit237","first-page":"393","article-title":"Basiliximab reduces the incidence of acute cellular rejection in live-related-donor kidney transplantation: a three-year prospective randomized trial","volume":"16","author":"Sheashaa","year":"2003 May","journal-title":"Journal of Nephrology"},{"issue":"8 Suppl","key":"10.1002\/14651858.CD003897.pub3-BIB0238|cit238","doi-asserted-by":"crossref","first-page":"S156","DOI":"10.1097\/00007890-200004271-00164","article-title":"Controlled trial of IL2R antibody basiliximab (Simulect) vs low dose OKT3 in cadaver kidney transplant recipients [abstract]","volume":"69","author":"Shidban","year":"2000","journal-title":"Transplantation"},{"issue":"Nov","key":"10.1002\/14651858.CD003897.pub3-BIB0239|cit239","first-page":"417A","article-title":"A prospective, randomized, phase IV comparative trial of Thymoglobulin\u00ae versus Simulect\u00ae for the prevention of delayed graft function and acute allograft rejection in renal transplant recipients. [abstract no: SA-PO551]","volume":"14","author":"Aswad","year":"2003","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Suppl 5","key":"10.1002\/14651858.CD003897.pub3-BIB0240|cit240","first-page":"352","article-title":"A prospective, randomized, phase IV comparative trial of thymoglobulin versus simulect for the prevention of delayed graft function and acute allograft rejection in renal transplant recipients [abstract]","volume":"3","author":"Shidban","year":"2003","journal-title":"American Journal of Transplantation"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD003897.pub3-BIB0241|cit241","first-page":"733A","article-title":"Quality of life improvement and lower costs associated with Simulect based induction therapy [abstract]","volume":"10","author":"Kaplan","year":"1999","journal-title":"Journal of the American Society of Nephrology"},{"issue":"2","key":"10.1002\/14651858.CD003897.pub3-BIB0242|cit242","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1034\/j.1399-0012.2001.150208.x","article-title":"Differential influence of azathioprine and mycophenolate mofetil on the disposition of basiliximab in renal transplant patients","volume":"15","author":"Kovarik","year":"2001","journal-title":"Clinical Transplantation"},{"key":"10.1002\/14651858.CD003897.pub3-BIB0243|cit243","unstructured":"Pescovitz M Kovarik JM Gerbeau C Simulect US-O1 Study Group Pharmacokinetics of basiliximab when coadministered with MMF in kidney transplantation [abstract no: 0112] XVIII International Congress of the Transplantation Society; 2000 Aug 27-Sept 1; Rome, Italy 2000"},{"issue":"Sept","key":"10.1002\/14651858.CD003897.pub3-BIB0245|cit244","first-page":"703A","article-title":"Effect of \"C2\" Cyclosporine Levels and Time to Initiation of Cyclosporine Therapy on Outcomes in Patients Receiving Neoral and Simulect [abstract]","volume":"11","author":"Pescovitz","year":"2000","journal-title":"Journal of the American Society of Nephrology"},{"issue":"5","key":"10.1002\/14651858.CD003897.pub3-BIB0244|cit245","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1034\/j.1399-0012.2002.02036.x","article-title":"Two-hour post-dose cyclosporine level is a better predictor than trough level of acute rejection of renal allografts","volume":"16","author":"Pescovitz","year":"2002","journal-title":"Clinical Transplantation"},{"issue":"5","key":"10.1002\/14651858.CD003897.pub3-BIB0246|cit246","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1093\/ndt\/16.5.1028","article-title":"An economic and quality-of-life assessment of basiliximab vs antithymocyte globulin immunoprophylaxis in renal transplantation","volume":"16","author":"Polsky","year":"2001","journal-title":"Nephrology Dialysis Transplantation"},{"key":"10.1002\/14651858.CD003897.pub3-BIB0247|cit247","unstructured":"Sollinger H Kaplan B Pescovitz M Philosophe B Roza A Brayman K A multicenter randomized trial of Simulect with early neoral vs atgam with delayed neoral in renal transplantation [abstract no:0113]] XVIII International Congress of the Transplantation Society; 2000 Aug 27-Sept 1; Rome, Italy 2000"},{"issue":"12","key":"10.1002\/14651858.CD003897.pub3-BIB0248|cit248","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1097\/00007890-200112270-00008","article-title":"Basiliximab versus antithymocyte globulin for prevention of acute renal allograft rejection","volume":"72","author":"Sollinger","year":"2001","journal-title":"Transplantation"},{"issue":"7","key":"10.1002\/14651858.CD003897.pub3-BIB0249|cit249","doi-asserted-by":"crossref","first-page":"S151","DOI":"10.1097\/00007890-199904150-00606","article-title":"A multicenter, randomized trial of simulect with early neoral vs atgam with delayed neoral in renal transplantation. A 6 month interim analysis [abstract]","volume":"67","author":"Sollinger","year":"1999","journal-title":"Transplantation"},{"key":"10.1002\/14651858.CD003897.pub3-BIB0250|cit250","unstructured":"Cantarovich D Giral M Hourmant M Dantal J Blancho G Soulillou JP 15-year results of a randomized study comparing anti-CD25 monoclonal antibody and antithymocyte globulin induction in kidney transplantation [abstract] XIXth International Congress of the Transplantation Society; 2002 Aug 25-30; Miami, FL 2002"},{"issue":"1 (Pt 2)","key":"10.1002\/14651858.CD003897.pub3-BIB0251|cit251","first-page":"1769","article-title":"Anti-IL2 receptor monoclonal antibody (33B3.1) in prophylaxis of early kidney rejection in humans: a randomized trial versus rabbit antithymocyte globulin","volume":"21","author":"Cantarovich","year":"1989","journal-title":"Transplantation Proceedings"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD003897.pub3-BIB0252|cit252","first-page":"308","article-title":"15-year results of a randomized study comparing anti-cd25 monoclonal antibody and antithymocyte globulin induction in kidney transplantation. [abstract]","volume":"17","author":"Cantarovich","year":"2002","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"17","key":"10.1002\/14651858.CD003897.pub3-BIB0253|cit253","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1056\/NEJM199004263221702","article-title":"Randomized controlled trial of a monoclonal antibody against the interleukin-2 receptor (33B3.1) as compared with rabbit antithymocyte globulin for prophylaxis against rejection of renal allografts","volume":"322","author":"Soulillou","year":"1990","journal-title":"New England Journal of Medicine"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD003897.pub3-BIB0254|cit254","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1097\/01.tp.0000332647.08253.2c","article-title":"Population pharmacokinetics of mycophenolic acid in combination with free or reduced doses of calcineurin inhibitors during the first week in renal transplant: the Symphony Study [abstract no: 105]","volume":"86","author":"Colom","year":"2008","journal-title":"Transplantation"},{"issue":"Abstracts","key":"10.1002\/14651858.CD003897.pub3-BIB0255|cit255","first-page":"563A","article-title":"Low-dose sirolimus in the first 8 weeks following renal transplantation accompanied by daclizumab induction, MMF and steroids: the experience of the SYMPHONY Study [abstract no: F-PO1078]","volume":"17","author":"Daloze","year":"2006","journal-title":"Journal of the American Society of Nephrology"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD003897.pub3-BIB0256|cit256","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1097\/01.tp.0000331916.77001.c8","article-title":"CNI minimisation with 2 G mycophenolate mofetil - what have we learned from the Symphony Study [abstract no: 964]","volume":"86","author":"Ekberg","year":"2008","journal-title":"Transplantation"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD003897.pub3-BIB0257|cit257","first-page":"160","article-title":"Cyclosporine, tacrolimus and sirolimus retained their distinct toxicity profiles despite low doses in the Symphony Study [abstract no: 55]","volume":"7","author":"Ekberg","year":"2007","journal-title":"American Journal of Transplantation"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD003897.pub3-BIB0258|cit258","first-page":"161","article-title":"The challenge of meeting target drug concentrations: experience from the Symphony study [abstract no:58]","volume":"7","author":"Ekberg","year":"2007","journal-title":"American Journal of Transplantation"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD003897.pub3-BIB0259|cit259","first-page":"300","article-title":"Low-dose sirolimus in the first 8 weeks following renal transplantation accompanied by daclizumab induction, MMF and steroids: the experience of the SYMPHONY Study [abstract no: 691]","volume":"6","author":"Ekberg","year":"2006","journal-title":"American Journal of Transplantation"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD003897.pub3-BIB0260|cit260","first-page":"320","article-title":"Improved outcomes after de novo renal transplantation: 2-year results from the Symphony Study [abstract no: 531]","volume":"8","author":"Ekberg","year":"2008","journal-title":"American Journal of Transplantation"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD003897.pub3-BIB0261|cit261","first-page":"336","article-title":"CNI sparing in de novo renal transplantation: 3-year results from the Symphony Study [abstract no: LB04]","volume":"8","author":"Ekberg","year":"2008","journal-title":"American Journal of Transplantation"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD003897.pub3-BIB0262|cit262","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1097\/01.tp.0000332146.48976.b4","article-title":"CNI sparing with mycophenolate mofetil in de novo renal transplantation: 3-year results from the Symphony Study [abstract no: 623]","volume":"86","author":"Ekberg","year":"2008","journal-title":"Transplantation"},{"issue":"25","key":"10.1002\/14651858.CD003897.pub3-BIB0263|cit263","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1056\/NEJMoa067411","article-title":"Reduced exposure to calcineurin inhibitors in renal transplantation","volume":"357","author":"Ekberg","year":"2007","journal-title":"New England Journal of Medicine"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD003897.pub3-BIB0264|cit264","first-page":"83","article-title":"Symphony - comparing standard immunosuppression to low-dose cyclosporine, tacrolimus or sirolimus in combination with MMF, daclizumab and corticosteroids in renal transplantation [abstract no: 49]","volume":"6","author":"Ekberg","year":"2006","journal-title":"American Journal of Transplantation"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD003897.pub3-BIB0265|cit265","first-page":"300","article-title":"Low-dose sirolimus in the first 8 weeks following renal transplantation accompanied by daclizumab induction, MMF and steroids: the experience of the Symphony Study [abstract no: 691]","volume":"6","author":"Ekberg","year":"2006","journal-title":"American Journal of Transplantation"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD003897.pub3-BIB0266|cit266","first-page":"210","article-title":"Characterization of acute rejections and associated relative risk factors in the Symphony Study [abstract no: 245]","volume":"7","author":"Frei","year":"2007","journal-title":"American Journal of Transplantation"},{"issue":"Abstracts","key":"10.1002\/14651858.CD003897.pub3-BIB0267|cit267","first-page":"69A","article-title":"SYMPHONY - comparing standard immunosuppression to low-dose cyclosporine, tacrolimus or sirolimus in combination with MMF, daclizumab and corticosteroids in renal transplantation [abstract no: F-FC152]","volume":"17","author":"Frei","year":"2006","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD003897.pub3-BIB0268|cit268","first-page":"177","article-title":"Pharmacokinetics of total and free mycophenolic acid in renal transplantation receiving standard-dose cyclosporine, low-dose cyclosporine, low-dose tacrolimus or low-dose sirolimus: the Symphony PK sub-study [abstract no: P342]","volume":"20","author":"Grinyo","year":"2007","journal-title":"Transplant International"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD003897.pub3-BIB0269|cit269","first-page":"345","article-title":"Pharmacokinetics of total and free mycophenolic acid (MPA) when mycophenolate mofetil (MMF) is administered with low-dose tacrolimus, low-dose cyclosporine, low-dose sirolimus or standard-dose cyclosporine in renal transplantation. Results of the Symphony PK substudy [abstract no: 824]","volume":"6","author":"Grinyo","year":"2006","journal-title":"American Journal of Transplantation"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD003897.pub3-BIB0270|cit270","first-page":"443","article-title":"Pharmacokinetics of total and free mycophenolic acid in renal transplantation receiving standard-dose cyclosporine, low-dose cyclosporine, low-dose tacrolimus or low-dose sirolimus: the Symphony PK sub-study","volume":"7","author":"Grinyo","year":"2007","journal-title":"American Journal of Transplantation"},{"issue":"7","key":"10.1002\/14651858.CD003897.pub3-BIB0271|cit271","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1093\/ndt\/gfp162","article-title":"The pharmacokinetics of mycophenolate mofetil in renal transplant recipients receiving standard-dose or low-dose cyclosporine, low-dose tacrolimus or low-dose sirolimus: the Symphony pharmacokinetic substudy","volume":"24","author":"Grinyo","year":"2009","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD003897.pub3-BIB0272|cit272","first-page":"439","article-title":"Blood pressure in the first year following renal transplantation is associated with immunosuppressive regimens: evidence from the Symphony study [abstract no:1137]","volume":"7","author":"Halloran","year":"2007","journal-title":"American Journal of Transplantation"},{"issue":"Abstracts","key":"10.1002\/14651858.CD003897.pub3-BIB0273|cit273","first-page":"227A","article-title":"Pharmacokinetics of total and free mycophenolic acid (MPA) when mycophenolate mofetil (MMF) is administered with low-dose tacrolimus, low-dose cyclosporine, low-dose sirolimus or standard-dose cyclosporine in renal transplantation. Results of the SYMPHONY PK substudy [abstract no: TH-PO564]","volume":"17","author":"Kuypers","year":"2006","journal-title":"Journal of the American Society of Nephrology"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD003897.pub3-BIB0274|cit274","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1097\/01.tp.0000330592.12123.8c","article-title":"Influence of MRP2 and UGT1A9 polimorphisms in the MPA pharmacokinetics in renal transplant substudy within the Symphony Study [abstract no: 2243]","volume":"86","author":"Lloberas","year":"2008","journal-title":"Transplantation"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD003897.pub3-BIB0275|cit275","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1097\/01.tp.0000330593.89252.b9","article-title":"Polymorphisms of the MDR1 gene in renal transplant recipients affect the PGP activity. Results of the pharmacogenetic substudy within the Symphony Study [abstract no: 2244]","volume":"86","author":"Lloberas","year":"2008","journal-title":"Transplantation"},{"issue":"Abstracts","key":"10.1002\/14651858.CD003897.pub3-BIB0276|cit276","first-page":"228A","article-title":"Health-related quality of life of patients receiving low toxicity immunosuppressive regimens [abstract no: TH-PO566]","volume":"17","author":"Oppenheimer","year":"2006","journal-title":"Journal of the American Society of Nephrology"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD003897.pub3-BIB0277|cit277","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1097\/01.tp.0000332649.93005.44","article-title":"Cost-effectiveness analysis of adverse events in low toxicity immunosuppressive regimens, preliminary results of the quality of life substudy within the Symphony Study [abstract no: 107]","volume":"86","author":"Oppenheimer","year":"2008","journal-title":"Transplantation"},{"issue":"2","key":"10.1002\/14651858.CD003897.pub3-BIB0278|cit278","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/j.transproceed.2005.01.071","article-title":"Basiliximab (Simulect) reduces acute rejection among sensitized kidney allograft recipients","volume":"37","author":"Tan","year":"2005","journal-title":"Transplantation Proceedings"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD003897.pub3-BIB0279|cit279","first-page":"266","article-title":"Basiliximab (simulect\u00ae) reduces acute rejection among sensitized kidney allograft recipients [abstract]","volume":"78","author":"Tan","year":"2004","journal-title":"Transplantation"},{"issue":"3","key":"10.1002\/14651858.CD003897.pub3-BIB0280|cit280","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.trim.2009.04.003","article-title":"Clinical rejection and persistent immune regulation in kidney transplant patients","volume":"21","author":"Hendrikx","year":"2009","journal-title":"Transplant Immunology"},{"issue":"3","key":"10.1002\/14651858.CD003897.pub3-BIB0281|cit281","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1046\/j.0306-5251.2003.01882.x","article-title":"Tacrolimus dose requirement in renal transplant recipients is significantly higher when used in combination with corticosteroids","volume":"56","author":"Hesselink","year":"2003","journal-title":"British Journal of Clinical Pharmacology"},{"issue":"Suppl 5","key":"10.1002\/14651858.CD003897.pub3-BIB0282|cit282","first-page":"482","article-title":"Tacrolimus dose requirement in renal transplant recipients is significantly higher when used in combination with corticosteroids [abstract]","volume":"3","author":"Hesselink","year":"2003","journal-title":"American Journal of Transplantation"},{"key":"10.1002\/14651858.CD003897.pub3-BIB0283|cit283","unstructured":"Ter Meulen CG van Riemsdijk IC Hene RJ Christiaans MHL van Gelder T Hilbrands LB A prospective randomized trial comparing steroid-free immunosuppression with limited steroid exposure on bone mineral density in the first year after renal transplantation [abstract no:0344] XIXth International Congress of the Transplantation Society; 2002 Aug 25-30; Miami, FL 2002"},{"issue":"2","key":"10.1002\/14651858.CD003897.pub3-BIB0284|cit284","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1046\/j.1523-1755.2003.00116.x","article-title":"Decreased renal excretion of soluble interleukin-2 receptor alpha after treatment with daclizumab","volume":"64","author":"ter Meulen","year":"2003","journal-title":"Kidney International"},{"issue":"3","key":"10.1002\/14651858.CD003897.pub3-BIB0285|cit285","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s00198-004-1628-z","article-title":"The influence of corticosteroids on quantitative ultrasound parameters of the calcaneus in the 1st year after renal transplantation","volume":"16","author":"ter Meulen","year":"2005","journal-title":"Osteoporosis International"},{"issue":"1","key":"10.1002\/14651858.CD003897.pub3-BIB0286|cit286","first-page":"101","article-title":"No important influence of limited steroid exposure on bone mass during the first year after renal transplantation: a prospective, randomized, multicenter study","volume":"78","author":"ter Meulen","year":"2004","journal-title":"Transplantation"},{"issue":"5","key":"10.1002\/14651858.CD003897.pub3-BIB0287|cit287","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1111\/j.1600-6143.2004.00419.x","article-title":"Steroid-withdrawal at 3 days after renal transplantation with anti-IL-2 receptor alpha therapy: a prospective, randomized, multicenter study","volume":"4","author":"ter Meulen","year":"2004","journal-title":"American Journal of Transplantation"},{"issue":"Suppl 8","key":"10.1002\/14651858.CD003897.pub3-BIB0288|cit288","first-page":"578","article-title":"Steroid withdrawal at three days after renal transplantation with anti il-2 receptor therapy: a prospective randomized multicenter trial. [abstract]","volume":"4","author":"Gelder","year":"2004","journal-title":"American Journal of Transplantation"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD003897.pub3-BIB0289|cit289","first-page":"171","article-title":"Anti-CD25 prophylaxis allows steroid-free renal transplantation in tacrolimus-based immunosuppression [abstract no: 133]","volume":"2","author":"Riemsdijk","year":"2002","journal-title":"American Journal of Transplantation"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD003897.pub3-BIB0290|cit290","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1097\/01.tp.0000332026.94443.e6","article-title":"ATG versus basiliximab induction therapy in kidney allograft recipients receiving dual immunosuppressive regimen: six-year results [abstract no: 800]","volume":"86","author":"Pascher","year":"2008","journal-title":"Transplantation"},{"issue":"6","key":"10.1002\/14651858.CD003897.pub3-BIB0291|cit291","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1016\/S0041-1345(03)00679-1","article-title":"ATG versus basiliximab induction therapy in renal allograft recipients receiving a dual immunosuppressive regimen: one-year results","volume":"35","author":"Tullius","year":"2003","journal-title":"Transplantation Proceedings"},{"issue":"Suppl 5","key":"10.1002\/14651858.CD003897.pub3-BIB0292|cit292","first-page":"478","article-title":"Induction therapy with ATG vs basiliximab (simulect) in renal allograft recipients: 1-year results of a prospective randomized, single center study [abstract]","volume":"3","author":"Tullius","year":"2003","journal-title":"American Journal of Transplantation"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD003897.pub3-BIB0293|cit293","first-page":"322","article-title":"ATG versus basiliximab induction therapy in kidney allograft recipients receiving a dual immunosuppressive regimen: six-year results [abstract no: 540]","volume":"8","author":"Ulrich","year":"2008","journal-title":"American Journal of Transplantation"},{"issue":"1","key":"10.1002\/14651858.CD003897.pub3-BIB0294|cit294","first-page":"201","article-title":"Ten-year follow-up of recipients of a kidney or heart transplant who received induction therapy with a monoclonal antibody against the interleukin-2 receptor","volume":"2","author":"Wabbijn","year":"2004","journal-title":"Experimental & Clinical Transplantation"},{"issue":"3","key":"10.1002\/14651858.CD003897.pub3-BIB0295|cit295","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1097\/00007890-199508000-00007","article-title":"A double-blind, placebo-controlled study of monoclonal anti-interleukin-2 receptor antibody (BT563) administration to prevent acute rejection after kidney transplantation","volume":"60","author":"Gelder","year":"1995","journal-title":"Transplantation"},{"issue":"6","key":"10.1002\/14651858.CD003897.pub3-BIB0296|cit296","first-page":"3221","article-title":"Long-term follow-up after induction treatment with monoclonal anti-interleukin-2 receptor antibody (BT563) in kidney allograft recipients: a double-blind, placebo-controlled trial","volume":"28","author":"Gelder","year":"1996","journal-title":"Transplantation Proceedings"},{"issue":"1","key":"10.1002\/14651858.CD003897.pub3-BIB0297|cit297","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1034\/j.1600-6143.2003.30109.x","article-title":"Pharmacokinetic and pharmacodynamic studies of one or two doses of daclizumab in renal transplantation","volume":"3","author":"Vincenti","year":"2003","journal-title":"American Journal of Transplantation"},{"issue":"2","key":"10.1002\/14651858.CD003897.pub3-BIB0298|cit298","first-page":"96","article-title":"Use of daclizumab in preventing delayed graft function in non-heart beating donor kidney transplantation in Newcastle upon Tyne","volume":"16","author":"Asher","year":"2004","journal-title":"Transplantationsmedizin - Organ der Deutschen Transplantationsgesellschaft"},{"issue":"9","key":"10.1002\/14651858.CD003897.pub3-BIB0299|cit299","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1111\/j.1432-2277.2005.00180.x","article-title":"Interleukin 2 receptor blockers may directly inhibit lymphocyte mediated ischaemia reperfusion injury","volume":"18","author":"Asir","year":"2005 Sep","journal-title":"Transplant International"},{"issue":"4","key":"10.1002\/14651858.CD003897.pub3-BIB0300|cit300","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1016\/j.transproceed.2005.02.079","article-title":"Evaluation of daclizumab to reduce delayed graft function in non-heart-beating renal transplantation: a prospective, randomized trial","volume":"37","author":"Wilson","year":"2005","journal-title":"Transplantation Proceedings"},{"key":"10.1002\/14651858.CD003897.pub3-BIB0301|cit301","unstructured":"Wilson C Brook NR Gok MA Gupta AJ Asher J Nicholson ML Evaluation of daclizumab to reduce delayed graft function in non-heartbeating renal transplantation: a prospective randomised trial [abstract] 3rd International Congress on Immunosuppression; 2004 Dec 8-11; San Diego (CA) 2004"},{"issue":"6","key":"10.1002\/14651858.CD003897.pub3-BIB0302|cit302","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1002\/bjs.4976","article-title":"Randomized clinical trial of daclizumab induction and delayed introduction of tacrolimus for recipients of non-heart-beating kidney transplants","volume":"92","author":"Wilson","year":"2005","journal-title":"British Journal of Surgery"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD003897.pub3-BIB0303|cit303","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1097\/00007890-200407271-01250","article-title":"A randomised controlled trial of daclizumab to reduce the incidence of delayed graft function in recipients of non-heart-beating renal grafts. [abstract]","volume":"78","author":"Wilson","year":"2004","journal-title":"Transplantation"},{"issue":"2","key":"10.1002\/14651858.CD003897.pub3-BIB0304|cit304","first-page":"29","article-title":"Prospective randomised trial of the use of Daclizumab in renal transplantation using kidneys from non heart beating donors","volume":"9","author":"Wilson","year":"2004","journal-title":"Annals of Transplantation"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD003897.pub3-BIB0305|cit305","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1097\/00007890-200407271-01253","article-title":"Two-dose daclizumab in conjunction with tacrolimus-based protocol in kidney transplantation - prospective, randomized study. [abstract]","volume":"78","author":"Yussim","year":"2004","journal-title":"Transplantation"},{"issue":"1","key":"10.1002\/14651858.CD003897.pub3-BIB0306|cit306","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/j.1399-0012.2008.00891.x","article-title":"A randomized trial of basiliximab with three different patterns of cyclosporin A initiation in renal transplant from expanded criteria donors and at high risk of delayed graft function","volume":"23","author":"Andres","year":"2009","journal-title":"Clinical Transplantation"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD003897.pub3-BIB0307|cit307","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1097\/00007890-200407271-00225","article-title":"Safety and efficacy of reduced or full dose of cyclosporine (neoral\u00ae) in combination with mycophenolatesodium (myfortic\u00ae), basiliximab (simulect\u00ae), and steroids in de novo kidney transplant recipients [abstract]","volume":"78","author":"Budde","year":"2004","journal-title":"Transplantation"},{"issue":"Suppl 11","key":"10.1002\/14651858.CD003897.pub3-BIB0308|cit308","first-page":"461","article-title":"Reduced cyclosporine exposure is safe and efficacious in combination with basiliximab, enteric-coated mycophenolate-sodium, and steroids [abstract no: 1195]","volume":"5","author":"Budde","year":"2005","journal-title":"American Journal of Transplantation"},{"issue":"3","key":"10.1002\/14651858.CD003897.pub3-BIB0309|cit309","doi-asserted-by":"crossref","first-page":"164","DOI":"10.5414\/CNP67164","article-title":"Reduced-exposure cyclosporine is safe and efficacious in de novo renal transplant recipients treated with enteric-coated mycophenolic acid and basiliximab","volume":"67","author":"Budde","year":"2007","journal-title":"Clinical Nephrology"},{"issue":"Abstracts","key":"10.1002\/14651858.CD003897.pub3-BIB0310|cit310","first-page":"565A","article-title":"Reduced-exposure cyclosporine is safe and efficacious in de novo renal transplant recipients treated with enteric-coated mycophenolic acid and basiliximab [abstract no: F-PO1088]","volume":"17","author":"Budde","year":"2006","journal-title":"Journal of the American Society of Nephrology"},{"issue":"5","key":"10.1002\/14651858.CD003897.pub3-BIB0311|cit311","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1016\/S0041-1345(02)03149-4","article-title":"Can acute rejection be prevented in SPK transplantation?","volume":"34","author":"Burke","year":"2002","journal-title":"Transplantation Proceedings"},{"issue":"Suppl 5","key":"10.1002\/14651858.CD003897.pub3-BIB0312|cit312","first-page":"322","article-title":"Can acute rejection be prevented in SPK transplantation? A randomized, prospective study with thymoglobulin\/zenapax induction, tacrolimus and steroid maintenance, comparing rapamycin with mycophenolate mofetil [abstract]","volume":"3","author":"Burke","year":"2003","journal-title":"American Journal of Transplantation"},{"issue":"Suppl 8","key":"10.1002\/14651858.CD003897.pub3-BIB0313|cit313","first-page":"562","article-title":"Can acute rejection be prevented in SPK transplantation? a randomized, prospective study with thymoglobulin\/zenapax induction, tacrolimus and steroid maintenance: comparing rapamycin with mycophenolate mofetil. [abstract]","volume":"4","author":"Burke","year":"2004","journal-title":"American Journal of Transplantation"},{"key":"10.1002\/14651858.CD003897.pub3-BIB0314|cit314","unstructured":"Burke GW Ciancio G Mattiazzi A Gomez C Rosen A Miller J Lower rate of acute rejection with rapamycin than with mycophenolate mofetil in kidney pancreas transplantation: a randomized, prospective study with thymoglobulin\/zenapax induction, tacrolimus and steroid maintenance: comparing rapamycin with mycopenolate mofetil [abstract] 3rd International Congress on Immunosuppression; 2004 Dec 8-11; San Diego (CA) 2004"},{"issue":"Suppl 11","key":"10.1002\/14651858.CD003897.pub3-BIB0315|cit315","first-page":"357","article-title":"Lower rate of acute rejection with rapamycin than with mycophenolate mofetil in kidney pancreas transplantation. A randomized, prospective study with thymoglobulin\/zenapax induction, tacrolimus and steroid maintenance: comparing rapamycin with mycophenolate mofetil. [abstract no: 789]","volume":"5","author":"Burke","year":"2005","journal-title":"American Journal of Transplantation"},{"key":"10.1002\/14651858.CD003897.pub3-BIB0316|cit316","unstructured":"Chadban S Campbell S Russ G Walker R Chapman J Pussell B A one-year, randomised, open label, parallel group study to investigate the safety and efficacy of enteric-coated mycophenolate sodium (EC-MPS) in combination with full dose or reduced dose cyclosporine microemulsion (CSA-ME), basiliximab and steroids in de novo kidney transplantation. [abstract no: 32] 24th Annual Scientific Meeting. Transplantation Society of Australia & New Zealand [TSANZ]; 2006 Mar 29-31; Canberra, Australia 2006 51"},{"issue":"6","key":"10.1002\/14651858.CD003897.pub3-BIB0317|cit317","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1097\/TP.0b013e318166927b","article-title":"Multicenter, randomized study of the use of everolimus with tacrolimus after renal transplantation demonstrates its effectiveness","volume":"85","author":"Chan","year":"2008","journal-title":"Transplantation"},{"issue":"Abstracts Issue","key":"10.1002\/14651858.CD003897.pub3-BIB0318|cit318","first-page":"678A","article-title":"Everolimus (RAD001) concentration is associated with risk reduction for acute rejection in de novo renal transplant recipients [abstract no: SA-PO2529]","volume":"19","author":"Chan","year":"2008","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Suppl 5","key":"10.1002\/14651858.CD003897.pub3-BIB0319|cit319","first-page":"450","article-title":"A randomized prospective trial of sirolimus vs cyclosporine in kidney transplantation: renal function and histology at two years [abstract]","volume":"3","author":"Flechner","year":"2003","journal-title":"American Journal of Transplantation"},{"key":"10.1002\/14651858.CD003897.pub3-BIB0320|cit320","unstructured":"Flechner SM Cook DJ Goldfarb D Modlin C Mastroianni B Savas K A randomized trial of sirolimus vs cyclosporine in kidney transplantation: impact on blood cells, lymphocyte subsets, and flow crossmatches [abstract] XIXth International Congress of the Transplantation Society; 2002 Aug 25-30; Miami, FL 2002"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD003897.pub3-BIB0321|cit321","first-page":"470","article-title":"A randomized trial of sirolimus vs cyclosporine in kidney transplantation: impact on blood cells, lymphocyte subsets, and flow crossmatches. [abstract no:1317]","volume":"2","author":"Flechner","year":"2002","journal-title":"American Journal of Transplantation"},{"issue":"8","key":"10.1002\/14651858.CD003897.pub3-BIB0322|cit322","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1097\/00007890-200210270-00002","article-title":"Kidney transplantation without calcineurin inhibitor drugs: a prospective, randomized trial of sirolimus versus cyclosporine","volume":"74","author":"Flechner","year":"2002","journal-title":"Transplantation"},{"issue":"7","key":"10.1002\/14651858.CD003897.pub3-BIB0323|cit323","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1097\/01.tp.0000258586.52777.4c","article-title":"Kidney transplantation with sirolimus and mycophenolate mofetil-based immunosuppression: 5-year results of a randomized prospective trial compared to calcineurin inhibitor drugs","volume":"83","author":"Flechner","year":"2007","journal-title":"Transplantation"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD003897.pub3-BIB0324|cit324","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1097\/00007890-200407271-00374","article-title":"Kidney transplantation with sirolimus and mycophenolate mofetil based immunosuppression preserves renal structure and function at two years compared to calcineurin inhibitor drugs. [abstract]","volume":"78","author":"Flechner","year":"2004","journal-title":"Transplantation"},{"issue":"11","key":"10.1002\/14651858.CD003897.pub3-BIB0325|cit325","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1111\/j.1600-6143.2004.00627.x","article-title":"De novo kidney transplantation without use of calcineurin inhibitors preserves renal structure and function at two years","volume":"4","author":"Flechner","year":"2004","journal-title":"American Journal of Transplantation"},{"issue":"Suppl 8","key":"10.1002\/14651858.CD003897.pub3-BIB0326|cit326","first-page":"296","article-title":"Kidney transplantation with sirolimus and mycophenolate mofetil based immunosuppression preserves renal structure and function compared to calcineurin inhibitor (cni) drugs. [abstract]","volume":"4","author":"Flechner","year":"2004","journal-title":"American Journal of Transplantation"},{"issue":"Abstracts","key":"10.1002\/14651858.CD003897.pub3-BIB0327|cit327","first-page":"69A","article-title":"Renal function and rejection incidence in de novo renal transplant patients randomized to steroid avoidance, steroid withdrawal or standard steroids [abstract no: F-FC153]","volume":"17","author":"Schena","year":"2006","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD003897.pub3-BIB0328|cit328","first-page":"84","article-title":"12-month results of a prospective, randomized trial of steroid avoidance, steroid withdrawal and standard steroids in de novo renal transplant patients receiving cyclosporine, enteric-coated mycophenolate sodium (EC-MPS, myfortic\u00ae) and basiliximab [abstract no: 54]","volume":"6","author":"Schena","year":"2006","journal-title":"American Journal of Transplantation"},{"issue":"Abstracts","key":"10.1002\/14651858.CD003897.pub3-BIB0329|cit329","first-page":"562A","article-title":"Comparison of metabolic parameters in renal transplant patients randomized to steroid avoidance, steroid withdrawal or standard steroids with a 12-month, randomized, multicenter trial [abstract no: F-PO1076]","volume":"17","author":"Vincenti","year":"2006","journal-title":"Journal of the American Society of Nephrology"},{"issue":"2","key":"10.1002\/14651858.CD003897.pub3-BIB0330|cit330","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1111\/j.1600-6143.2007.02057.x","article-title":"A randomized, multicenter study of steroid avoidance, early steroid withdrawal or standard steroid therapy in kidney transplant recipients","volume":"8","author":"Vincenti","year":"2008","journal-title":"American Journal of Transplantation"},{"key":"10.1002\/14651858.CD003897.pub3-BIB0331|cit331","unstructured":"Walker R Campbell S Chadban S Kanellis J Pilmore H Russ G Preliminary results of a 12-month study with enteric-coated mycophenolate sodium (EC-MPS), basiliximab, and neoral C-2 comparing a regimen without steroids or short-term use of steroids with standard steroid treatment in de novo kidney recipients. [abstract no: 34] 24th Annual Scientific Meeting. Transplantation Society of Australia & New Zealand [TSANZ]; 2006 Mar 29-31; Canberra, Australia 2006 52"},{"issue":"Suppl","key":"10.1002\/14651858.CD003897.pub3-BIB0332|cit332","first-page":"A214","article-title":"Preliminary results of a 12-month study with enteric-coated mycophenolate sodium (EC-MPS), basiliximab, and neoral C-2 comparing two investigational steroid regimens (without steroids or short-term use of steroids) with standard steroid treatment in de novo kidney recipients [abstract no: T-PO50027]","volume":"10","author":"Walker","year":"2005","journal-title":"Nephrology"},{"issue":"6","key":"10.1002\/14651858.CD003897.pub3-BIB0333|cit333","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1681\/ASN.2007091001","article-title":"Long-term efficacy and safety of a calcineurin inhibitor-free regimen in live-donor renal transplant recipients","volume":"19","author":"Hamdy","year":"2008","journal-title":"Journal of the American Society of Nephrology"},{"issue":"10","key":"10.1002\/14651858.CD003897.pub3-BIB0334|cit334","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1111\/j.1600-6143.2005.01064.x","article-title":"Comparison of sirolimus with low-dose tacrolimus versus sirolimus-based calcineurin inhibitor-free regimen in live donor renal transplantation","volume":"5","author":"Hamdy","year":"2005","journal-title":"American Journal of Transplantation"},{"key":"10.1002\/14651858.CD003897.pub3-BIB0335|cit335","doi-asserted-by":"crossref","first-page":"S444","DOI":"10.1111\/tri.1992.5.s1.444","article-title":"Prophylactic use of the IL-2 receptor-specific monoclonal antibody LO-Tact-1 with cyclosporin A and steroids in renal transplantation","volume":"5 Suppl 1","author":"Hiesse","year":"1992","journal-title":"Transplant International"},{"issue":"Suppl 8","key":"10.1002\/14651858.CD003897.pub3-BIB0336|cit336","first-page":"442","article-title":"Treatment of kidney transplant patients with the novel co-stimulatory blocker LEA29y (BMS-224818) and antiil2 receptor antibody does not impede the development of regulatory t cells. [abstract]","volume":"4","author":"Hirose","year":"2004","journal-title":"American Journal of Transplantation"},{"issue":"12","key":"10.1002\/14651858.CD003897.pub3-BIB0337|cit337","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1046\/j.1600-6135.2003.00242.x","article-title":"Influence of delayed initiation of cyclosporine on everolimus pharmacokinetics in de novo renal transplant patients","volume":"3","author":"Kovarik","year":"2003","journal-title":"American Journal of Transplantation"},{"issue":"Suppl","key":"10.1002\/14651858.CD003897.pub3-BIB0338|cit338","first-page":"A1","article-title":"Excellent graft function in de novo kidney transplant recipients treated with Certican\u00ae, Simulect\u00ae and reduced Neoral\u00ae exposure: 24 month result [abstract no: FC-50002]","volume":"10","author":"Campbell","year":"2005","journal-title":"Nephrology"},{"key":"10.1002\/14651858.CD003897.pub3-BIB0339|cit339","unstructured":"Campbell S Eris J Walker R Russ G Kanellis J RAD2307 International Study Group Excellent graft function in kidney transplant recipients treated with everolimus, low-CsA and basiliximab at 24 months. [abstract no: 36] 24th Annual Scientific Meeting.Transplantation Society of Australia & New Zealand [TSANZ]; 2006 Mar 29-31; Canberra, Australia 2006 53"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD003897.pub3-BIB0340|cit340","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1097\/00007890-200407271-00095","article-title":"Excellent graft function in de novo kidney transplant recipients treated with certican\u00ae, simulect\u00ae and reduced neoral\u00ae exposure: 12-month results [abstract]","volume":"78","author":"Eris","year":"2004","journal-title":"Transplantation"},{"key":"10.1002\/14651858.CD003897.pub3-BIB0341|cit341","unstructured":"Eris J Campbell S Walker R Russ G Stambe C RAD2307 International Study Group Excellent graft function in de novo transplant recipients treated with everolimus, reduced dose neoral and simulect: 6 months analysis. [abstract] 22nd Annual Scientific Meeting Transplantation Society of Australia & New Zealand; 2004 Mar 31-Apr 2; Canberra, Australia 2004 33"},{"key":"10.1002\/14651858.CD003897.pub3-BIB0342|cit342","unstructured":"Kraemer BK Bourbigot B Vitko S Rigotti P Caicedo L de Boccardo G Excellent graft function in kidney transplant recipients treated with everolimus, low-CSA and basiliximab at 24 months [abstract no: PO-437] 12th Congress of the European Society for Organ Transplantation (ESOT); 2005 Oct 15-19; Geneva, Switzerland 2005"},{"issue":"3","key":"10.1002\/14651858.CD003897.pub3-BIB0343|cit343","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1016\/j.transproceed.2004.09.026","article-title":"Graft function, cardiovascular risk factors, and sex hormones in renal transplant recipients on an immunosuppressive regimen of everolimus, reduced dose of cyclosporine, and basiliximab","volume":"37","author":"Kramer","year":"2005","journal-title":"Transplantation Proceedings"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD003897.pub3-BIB0344|cit344","first-page":"786","article-title":"Excellent graft function in de novo kidney transplant recipients treated with concentration controlled everolimus, reduced neoral exposure and basiliximab: 6 months analysis [abstract]","volume":"18","author":"Kramer","year":"2003","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Suppl 11","key":"10.1002\/14651858.CD003897.pub3-BIB0345|cit345","first-page":"414","article-title":"Excellent graft function in de novo kidney transplant recipients treated with Certican\u00a9, Simulect\u00a9 and reduced Neoral\u00a9 exposure: 24 month result [abstract no: 1011]","volume":"5","author":"Leone","year":"2005","journal-title":"American Journal of Transplantation"},{"key":"10.1002\/14651858.CD003897.pub3-BIB0346|cit346","unstructured":"Rigotti P Excellent Graft Function in De Novo Kidney Transplant Recipients Treated with Concentration Controlled Everolimus, Reduced Neoral Exposure and Simulect: 6 Months Analysis [abstract no:2] European Society of Transplantation; 2003 Sept; Venice, Italy 2003"},{"issue":"Suppl 5","key":"10.1002\/14651858.CD003897.pub3-BIB0347|cit347","first-page":"462","article-title":"Efficacy and safety of 2 doses of everolimus combined with reduced dose neoral in de novo kidney transplant recipients: 6 months analysis [abstract]","volume":"3","author":"Tedesco","year":"2003","journal-title":"American Journal of Transplantation"},{"issue":"1","key":"10.1002\/14651858.CD003897.pub3-BIB0348|cit348","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1432-2277.2006.00414.x","article-title":"12-month safety and efficacy of everolimus with reduced exposure cyclosporine in de novo renal transplant recipients","volume":"20","author":"Tedesco-Silva","year":"2007","journal-title":"Transplant International"},{"issue":"4","key":"10.1002\/14651858.CD003897.pub3-BIB0349|cit349","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1111\/j.1600-6143.2004.00389.x","article-title":"Everolimus with optimized cyclosporine dosing in renal transplant recipients: 6-month safety and efficacy results of two randomized studies","volume":"4","author":"Vitko","year":"2004","journal-title":"American Journal of Transplantation"},{"issue":"Suppl 8","key":"10.1002\/14651858.CD003897.pub3-BIB0350|cit350","first-page":"297","article-title":"Excellent graft function in de novo kidney transplant recipients treated with certican\u00ae, simulect\u00ae and reduced neoral\u00ae exposure: 12-month results. [abstract]","volume":"4","author":"Whelchel","year":"2004","journal-title":"American Journal of Transplantation"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD003897.pub3-BIB0351|cit351","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1097\/00007890-200407271-01239","article-title":"Lowering cyclosporine dose is not associated with an increased risk of gastro-intestinal adverse events nor the need for dosage decrease of mycophenolate mofetil [abstract no: P743]","volume":"78","author":"Kreis","year":"2004","journal-title":"Transplantation"},{"issue":"Suppl 5","key":"10.1002\/14651858.CD003897.pub3-BIB0352|cit352","first-page":"476","article-title":"Daclizumab and mycophenolate mofetil in renal transplant recipients: 2-year outcome after early reduction of cyclosporine [abstract]","volume":"3","author":"Kreis","year":"2003","journal-title":"American Journal of Transplantation"},{"issue":"Suppl 7","key":"10.1002\/14651858.CD003897.pub3-BIB0353|cit353","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1034\/j.1399-0012.16.s7.4.x","article-title":"Daclizumab induction\/tacrolimus sparing: a randomized prospective trial in renal transplantation","volume":"16","author":"Light","year":"2002","journal-title":"Clinical Transplantation"},{"issue":"11","key":"10.1002\/14651858.CD003897.pub3-BIB0354|cit354","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1097\/01.tp.0000235823.09788.f6","article-title":"Living related kidney transplantation without calcineurin inhibitors: Initial experience in a Mexican center","volume":"82","author":"Martinez-Mier","year":"2006","journal-title":"Transplantation"},{"issue":"5","key":"10.1002\/14651858.CD003897.pub3-BIB0355|cit355","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1111\/j.1600-6143.2008.02167.x","article-title":"Incidence of PTLD in pediatric renal transplant recipients receiving basiliximab, calcineurin inhibitor, sirolimus and steroids","volume":"8","author":"McDonald","year":"2008","journal-title":"American Journal of Transplantation"},{"key":"10.1002\/14651858.CD003897.pub3-BIB0356|cit356","first-page":"829A","article-title":"Treatment of high-risk renal transplant recipients with EC-MPS (Myfortic\u00ae) is safe and efficacious [abstract no: PUB216]","volume":"16","author":"Bresnahan","year":"2005","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Suppl 11","key":"10.1002\/14651858.CD003897.pub3-BIB0357|cit357","first-page":"190","article-title":"Safety and efficacy of EC-MPS in combination with simulect and neoral in de novo renal transplant high-risk recipients [abstract no: 135]","volume":"5","author":"Cibrik","year":"2005","journal-title":"American Journal of Transplantation"},{"issue":"Suppl 8","key":"10.1002\/14651858.CD003897.pub3-BIB0358|cit358","first-page":"218","article-title":"Enteric-coated mycophenolate sodium in combination with optimized neoral dosing, basiliximab, and steroids results in good efficacy and renal function in renal transplant recipients in the first six months [abstract no:220]","volume":"4","author":"Cibrik","year":"2008","journal-title":"American Journal of Transplantation"},{"issue":"2","key":"10.1002\/14651858.CD003897.pub3-BIB0359|cit359","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/j.1399-0012.2006.00622.x","article-title":"Renal function with cyclosporine C2 monitoring, enteric-coated mycophenolate sodium and basiliximab: a 12-month randomized trial in renal transplant recipients","volume":"21","author":"Cibrik","year":"2007","journal-title":"Clinical Transplantation"},{"issue":"Oct Abstracts I","key":"10.1002\/14651858.CD003897.pub3-BIB0360|cit360","first-page":"299A","article-title":"Optimized Neoral C2 monitoring in combination with enteric-coated mycophenolic acid, basiliximab and steroids is effective, safe and tolerable: 12-month results of a multicenter, randomized, prospective trial. [abstract no: F-PO1068]","volume":"15","author":"Meier-Kriesche","year":"2004","journal-title":"Journal of the American Society of Nephrology"},{"issue":"2","key":"10.1002\/14651858.CD003897.pub3-BIB0361|cit361","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/j.transproceed.2004.11.033","article-title":"A randomized trial of steroid avoidance in renal transplant patients treated with everolimus and cyclosporine","volume":"37","author":"Montagnino","year":"2005","journal-title":"Transplantation Proceedings"},{"issue":"2","key":"10.1002\/14651858.CD003897.pub3-BIB0362|cit362","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1093\/ndt\/gfm621","article-title":"A randomized exploratory trial of steroid avoidance in renal transplant patients treated with everolimus and low-dose cyclosporine","volume":"23","author":"Montagnino","year":"2008","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"5 Pt 1","key":"10.1002\/14651858.CD003897.pub3-BIB0363|cit363","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1111\/j.1600-6143.2006.01291.x","article-title":"Impact of early or delayed cyclosporine on delayed graft function in renal transplant recipients: a randomized, multicenter study","volume":"6","author":"Kamar","year":"2006","journal-title":"American Journal of Transplantation"},{"issue":"3","key":"10.1002\/14651858.CD003897.pub3-BIB0364|cit364","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1399-0012.2007.00660.x","article-title":"Renal function with delayed or immediate cyclosporine microemulsion in combination with enteric-coated mycophenolate sodium and steroids: results of follow up to 30 months post-transplant","volume":"21","author":"Mourad","year":"2007","journal-title":"Clinical Transplantation"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD003897.pub3-BIB0366|cit365","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1097\/00007890-200407271-01219","article-title":"Assessment of two strategies of neoral\u00ae administration, early versus delayed, on renal function and efficacy in de novo renal transplant patients receiving myfortic\u00ae, steroids and anti-il2r antibodies: 6 months interim results. [abstract]","volume":"78","author":"Mourad","year":"2004","journal-title":"Transplantation"},{"issue":"2","key":"10.1002\/14651858.CD003897.pub3-BIB0365|cit366","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.transproceed.2004.12.263","article-title":"Assessment of two strategies of neoral administration, early versus delayed, on renal function and efficacy in de novo renal transplant patients receiving myfortic, steroids, and anti-IL2R antibodies: 12-month results of a randomized, multicentre, open, prospective controlled study","volume":"37","author":"Mourad","year":"2005","journal-title":"Transplantation Proceedings"},{"issue":"Suppl 8","key":"10.1002\/14651858.CD003897.pub3-BIB0367|cit367","first-page":"219","article-title":"Assessment of two neoral\u00ae administration strategies on renal function and efficacy in de novo renal transplant patients receiving enteric-coated mycophenolate sodium, steroids and anti-il2r antibodies: 6 months interim analysis of a randomized, multicentre, open, prospective controlled study.[abstract]","volume":"4","author":"Mourad","year":"2004","journal-title":"American Journal of Transplantation"},{"issue":"9","key":"10.1002\/14651858.CD003897.pub3-BIB0368|cit368","doi-asserted-by":"crossref","first-page":"2860","DOI":"10.1016\/j.transproceed.2006.08.119","article-title":"Tolerability of enteric-coated mycophenolate sodium to 1 year in combination with cyclosporine and corticosteroids in renal transplant recipients","volume":"38","author":"Rostaing","year":"2006","journal-title":"Transplantation Proceedings"},{"issue":"Suppl 8","key":"10.1002\/14651858.CD003897.pub3-BIB0369|cit369","first-page":"219","article-title":"Safety and tolerability of enteric-coated mycophenolate sodium in combination with steroids and two regimen of neoral\u00ae, in denovo kidney transplant recipients: 6 months interim results. A randomized, multicentre, open, prospective controlled study. [abstract]","volume":"4","author":"Rostaing","year":"2004","journal-title":"American Journal of Transplantation"},{"issue":"5","key":"10.1002\/14651858.CD003897.pub3-BIB0370|cit370","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/j.transproceed.2007.03.064","article-title":"Efficacy and safety of enteric-coated mycophenolate sodium in de novo renal transplant recipients: pooled data from three 12-month multicenter, open-label, prospective studies","volume":"39","author":"Legendre","year":"2007","journal-title":"Transplantation Proceedings"},{"issue":"Suppl 6","key":"10.1002\/14651858.CD003897.pub3-BIB0371|cit371","first-page":"vi93","article-title":"Improving quality of life after steroid avoidance immunosuppression regimen in live donor renal allotransplant recipients - a prospective randomized controlled study single center experience (two year follow up) [abstract no: FP222]","volume":"22","author":"Neamatalla","year":"2007","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD003897.pub3-BIB0372|cit372","first-page":"iv263","article-title":"Steroid avoidance immunosuppression regimen in live donor renal allotransplant recipients - a prospective randomized controlled study single center experience (one year follow up) [abstract no: SP734]","volume":"21","author":"Nematalla","year":"2006","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"2","key":"10.1002\/14651858.CD003897.pub3-BIB0373|cit373","first-page":"673","article-title":"Steroid-avoidance immunosuppression regimen in live-donor renal allotransplant recipients: a prospective, randomized, controlled study","volume":"5","author":"Nematalla","year":"2007","journal-title":"Experimental & Clinical Transplantation"},{"issue":"6","key":"10.1002\/14651858.CD003897.pub3-BIB0374|cit374","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1046\/j.1523-1755.2003.00038.x","article-title":"Health-related fitness and quality of life following steroid withdrawal in renal transplant recipients","volume":"63","author":"Painter","year":"2003","journal-title":"Kidney International"},{"issue":"Suppl 8","key":"10.1002\/14651858.CD003897.pub3-BIB0375|cit375","first-page":"251","article-title":"Pharmacokinetics, safety and efficacy of mycophenolate mofetil in combination with sirolimus vs cyclosporine in renal transplant patients [abstract]","volume":"4","author":"Pescovitz","year":"2004","journal-title":"American Journal of Transplantation"},{"issue":"6","key":"10.1002\/14651858.CD003897.pub3-BIB0376|cit376","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1111\/j.1365-2125.2007.02934.x","article-title":"Pharmacokinetics, safety, and efficacy of mycophenolate mofetil in combination with sirolimus or ciclosporin in renal transplant patients","volume":"64","author":"Pescovitz","year":"2007","journal-title":"British Journal of Clinical Pharmacology"},{"issue":"Sept Program &","key":"10.1002\/14651858.CD003897.pub3-BIB0377|cit377","first-page":"703A","article-title":"Analysis of patient and graft outcomes in daclizumab based induction immunosuppression using neoral vs tacrolimus [abstract]","volume":"11","author":"Provenzano","year":"2000","journal-title":"Journal of the American Society of Nephrology"},{"issue":"9","key":"10.1002\/14651858.CD003897.pub3-BIB0378|cit378","doi-asserted-by":"crossref","first-page":"2622","DOI":"10.1681\/ASN.2006030227","article-title":"Untreated rejection in 6-month protocol biopsies is not associated with fibrosis in serial biopsies or with loss of graft function","volume":"17","author":"Scholten","year":"2006","journal-title":"Journal of the American Society of Nephrology"},{"issue":"25","key":"10.1002\/14651858.CD003897.pub3-BIB0379|cit379","first-page":"4861","article-title":"Influences of single-dose Basiliximab on Foxp3mRNA, CD4+CD25+ regulatory T cells, interleukin-2 and interleukin-2 receptor in the peripheral blood of renal transplantation recipients","volume":"11","author":"Tian","year":"2007","journal-title":"Journal of Clinical Rehabilitative Tissue Engineering Research"},{"issue":"Oct","key":"10.1002\/14651858.CD003897.pub3-BIB0380|cit380","first-page":"236A","article-title":"3 months interim results of a 12-month study with enteric-coated mycophenolate sodium (EC-MPS, Myfortic\u00a9), basiliximab, and neoral C-2 comparing different steroid protocols in de novo kidney recipients [abstract no: TH-PO544]","volume":"16","author":"Vincenti","year":"2005","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Suppl 11","key":"10.1002\/14651858.CD003897.pub3-BIB0381|cit381","first-page":"548","article-title":"Preliminary 3-month results comparing immunosuppressive regimens of enteric-coated mycophenolate sodium (EC-MPS) without steroids vs short-term use of steroids vs standard steroid treatment including basiliximab, and neoral C-2 in de novo kidney recipients [abstract no: 1542]","volume":"5","author":"Vincenti","year":"2005","journal-title":"American Journal of Transplantation"},{"issue":"1","key":"10.1002\/14651858.CD003897.pub3-BIB0382|cit382","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.trim.2008.01.005","article-title":"Short-term anti-CD25 monoclonal antibody treatment and neogenetic CD4(+)CD25(high) regulatory T cells in kidney transplantation","volume":"19","author":"Wang","year":"2008","journal-title":"Transplant Immunology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD003897.pub3-BIB0383|cit383","first-page":"287","article-title":"Randomized trial of Rituximab vs standard of care for B cell dense acute renal transplant rejection [abstract no: 538]","volume":"7","author":"Sarwal","year":"2007","journal-title":"American Journal of Transplantation"},{"issue":"12","key":"10.1002\/14651858.CD003897.pub3-BIB0384|cit384","doi-asserted-by":"crossref","first-page":"2607","DOI":"10.1111\/j.1600-6143.2008.02411.x","article-title":"A randomized, prospective trial of rituximab for acute rejection in pediatric renal transplantation","volume":"8","author":"Zarkhin","year":"2008","journal-title":"American Journal of Transplantation"},{"key":"10.1002\/14651858.CD003897.pub3-BIB0385|cit385","article-title":"Chapter 8 Transplantation","volume-title":"ANZDATA Registry Report 2008. available from http:\/\/www.anzdata.org.au\/v1\/annual_reports_download.html","author":"Campbell","year":"2008"},{"issue":"8","key":"10.1002\/14651858.CD003897.pub3-BIB0386|cit386","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1001\/jama.1996.03540080059030","article-title":"Improving the quality of reporting of randomized controlled trials. The CONSORT statement","volume":"276","author":"Begg","year":"1996","journal-title":"JAMA"},{"issue":"10","key":"10.1002\/14651858.CD003897.pub3-BIB0387|cit387","doi-asserted-by":"crossref","first-page":"655","DOI":"10.2165\/00063030-200115100-00003","article-title":"Role of anti-interleukin-2 receptor antibodies in kidney transplantation","volume":"15","author":"Cibrik","year":"2001","journal-title":"Biodrugs"},{"key":"10.1002\/14651858.CD003897.pub3-BIB0388|cit388","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1002\/9780470693926.ch6","article-title":"Obtaining individual patient data from randomised controlled trials","volume-title":"Systematic reviews in health care","author":"Clarke","year":"2001"},{"issue":"7406","key":"10.1002\/14651858.CD003897.pub3-BIB0389|cit389","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1136\/bmj.327.7406.65","article-title":"Balancing benefits and harms in health care","volume":"327","author":"Cuervo","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD003897.pub3-BIB0390|cit390","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/9780470693926.ch15","article-title":"Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis","volume-title":"Systematic reviews in health care: meta-analysis in context","author":"Deeks","year":"2001"},{"issue":"6964","key":"10.1002\/14651858.CD003897.pub3-BIB0391|cit391","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1136\/bmj.309.6964.1286","article-title":"Identifying relevant studies for systematic reviews","volume":"309","author":"Dickersin","year":"1994","journal-title":"BMJ"},{"issue":"7109","key":"10.1002\/14651858.CD003897.pub3-BIB0392|cit392","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"issue":"2","key":"10.1002\/14651858.CD003897.pub3-BIB0393|cit393","first-page":"130","article-title":"How to identify randomized controlled trials in MEDLINE: ten years on","volume":"94","author":"Glanville","year":"2006","journal-title":"Journal of the Medical Library Association"},{"issue":"3","key":"10.1002\/14651858.CD003897.pub3-BIB0394|cit394","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S0966-3274(00)00021-6","article-title":"Daclizumab (Zenapax) inhibits early interleukin-2 receptor signal transduction events","volume":"8","author":"Goebel","year":"2000","journal-title":"Transplant Immunology"},{"issue":"7414","key":"10.1002\/14651858.CD003897.pub3-BIB0395|cit395","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD003897.pub3-BIB0396|cit396","doi-asserted-by":"crossref","DOI":"10.1002\/9780470712184","volume-title":"Cochrane handbook for systematic reviews of interventions","author":"Higgins","year":"2008"},{"issue":"2","key":"10.1002\/14651858.CD003897.pub3-BIB0397|cit397","first-page":"108","article-title":"Immunosuppressive agents in organ transplantation: past, present and future","volume":"20","author":"Hong","year":"2000","journal-title":"Seminars in Nephrology"},{"key":"10.1002\/14651858.CD003897.pub3-BIB0398|cit398","unstructured":"Lefebvre C McDonald S Development of a sensitive search strategy for reports of randomized controlled trials in EMBASE Fourth International Cochrane Colloquium, Adelaide, Australia, 20-24 October 1996"},{"key":"10.1002\/14651858.CD003897.pub3-BIB0399|cit399","doi-asserted-by":"crossref","unstructured":"Lefebvre C Manheimer E Glanville J Chapter 6: Searching for studies. In Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 (updated February 2008). The Cochrane Collaboration. Available from www.cochrane-handbook.org","DOI":"10.1002\/9780470712184.ch6"},{"issue":"9193","key":"10.1002\/14651858.CD003897.pub3-BIB0400|cit400","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1016\/S0140-6736(99)04149-5","article-title":"Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses","volume":"354","author":"Moher","year":"1999","journal-title":"Lancet"},{"issue":"7","key":"10.1002\/14651858.CD003897.pub3-BIB0401|cit401","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1093\/ndt\/gfp174","article-title":"The cost-effectiveness of induction immunosuppression in kidney transplantation","volume":"24","author":"Morton","year":"2009","journal-title":"Nephrology Dialysis Transplantation"},{"key":"10.1002\/14651858.CD003897.pub3-BIB0402|cit402","unstructured":"Rockville M Richmond V Annual Report of the US Scientific Registry of Transplant Recipients and the Organ Procurement and transplantation Network: Transplant data 1989-1998 2008 Annual Report of the U.S. Organ Procurement and Transplantation Network and the Scientific Registry of Transplant Recipients: Transplant Data 1998-2007 http:\/\/optn.transplant.hrsa.gov\/data\/annualReport.asp 2008"},{"issue":"9","key":"10.1002\/14651858.CD003897.pub3-BIB0403|cit403","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1093\/ndt\/16.9.1756","article-title":"Anti-interleukin-2 receptor antibodies: basiliximab and daclizumab","volume":"16","author":"Pascual","year":"2001","journal-title":"Nephrology Dialysis Transplantation"},{"key":"10.1002\/14651858.CD003897.pub3-BIB0404|cit404","unstructured":"Willis NS Mitchell R Higgins GY Webster AC Craig JC Cochrane Renal Group About The Cochrane Collaboration (Cochrane Review Groups (CRGs)) 2009, Issue 4. Art. No.: RENAL (accessed November 2009)"},{"key":"10.1002\/14651858.CD003897.pub3-BIB0405|cit405","unstructured":"Transplant Activity report 2008-2009, section 3 Kidney Activity NHS Blood and Transplant, Transplant Activity in the UK. available at: http:\/\/www.organdonation.nhs.uk\/ukt\/statistics\/statistics.jsp"},{"key":"10.1002\/14651858.CD003897.pub3-BIB0406|cit406","article-title":"Chapter 11: Measures of Care in Adult Renal Transplant Recipients in the UK","volume-title":"The Renal Association UK Renal Registry Tenth Annual Report","author":"Ravanan","year":"December 2007"},{"issue":"6","key":"10.1002\/14651858.CD003897.pub3-BIB0407|cit407","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1034\/j.1399-3046.2001.00062.x","article-title":"Tailoring immunosuppressive therapy for renal transplant recipients","volume":"5","author":"Vanrenterghem","year":"2001","journal-title":"Pediatric Transplantation"},{"issue":"4","key":"10.1002\/14651858.CD003897.pub3-BIB0408|cit408","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003897","article-title":"Interleukin 2 receptor antagonists for kidney transplant recipients","author":"Webster","year":"2003","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD003897.pub3-BIB0409|cit409","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003897.pub2","article-title":"Interleukin 2 receptor antagonists for kidney transplant recipients","author":"Webster","year":"2004","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD003897.pub3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,15]],"date-time":"2024-01-15T14:37:11Z","timestamp":1705329431000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD003897.pub3"}},"subtitle":[],"editor":[{"name":"Cochrane Kidney and Transplant Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2010,1,20]]},"references-count":409,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2014,5]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd003897.pub3","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,1,20]]}}}